Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls

‘Multistage testing with adaptive designs’ was the title of an article by Peter Bauer that appeared 1989 in the German journal Biometrie und Informatik in Medizin und Biologie. The journal does not exist anymore but the methodology found widespread interest in the scientific community over the past...

Full description

Saved in:
Bibliographic Details
Published inStatistics in medicine Vol. 35; no. 3; pp. 325 - 347
Main Authors Bauer, Peter, Bretz, Frank, Dragalin, Vladimir, König, Franz, Wassmer, Gernot
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 10.02.2016
Wiley Subscription Services, Inc
John Wiley and Sons Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract ‘Multistage testing with adaptive designs’ was the title of an article by Peter Bauer that appeared 1989 in the German journal Biometrie und Informatik in Medizin und Biologie. The journal does not exist anymore but the methodology found widespread interest in the scientific community over the past 25 years. The use of such multistage adaptive designs raised many controversial discussions from the beginning on, especially after the publication by Bauer and Köhne 1994 in Biometrics: Broad enthusiasm about potential applications of such designs faced critical positions regarding their statistical efficiency. Despite, or possibly because of, this controversy, the methodology and its areas of applications grew steadily over the years, with significant contributions from statisticians working in academia, industry and agencies around the world. In the meantime, such type of adaptive designs have become the subject of two major regulatory guidance documents in the US and Europe and the field is still evolving. Developments are particularly noteworthy in the most important applications of adaptive designs, including sample size reassessment, treatment selection procedures, and population enrichment designs. In this article, we summarize the developments over the past 25 years from different perspectives. We provide a historical overview of the early days, review the key methodological concepts and summarize regulatory and industry perspectives on such designs. Then, we illustrate the application of adaptive designs with three case studies, including unblinded sample size reassessment, adaptive treatment selection, and adaptive endpoint selection. We also discuss the availability of software for evaluating and performing such designs. We conclude with a critical review of how expectations from the beginning were fulfilled, and – if not – discuss potential reasons why this did not happen. © 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd.
AbstractList ‘Multistage testing with adaptive designs’ was the title of an article by Peter Bauer that appeared 1989 in the German journal Biometrie und Informatik in Medizin und Biologie . The journal does not exist anymore but the methodology found widespread interest in the scientific community over the past 25 years. The use of such multistage adaptive designs raised many controversial discussions from the beginning on, especially after the publication by Bauer and Köhne 1994 in Biometrics : Broad enthusiasm about potential applications of such designs faced critical positions regarding their statistical efficiency. Despite, or possibly because of, this controversy, the methodology and its areas of applications grew steadily over the years, with significant contributions from statisticians working in academia, industry and agencies around the world. In the meantime, such type of adaptive designs have become the subject of two major regulatory guidance documents in the US and Europe and the field is still evolving. Developments are particularly noteworthy in the most important applications of adaptive designs, including sample size reassessment, treatment selection procedures, and population enrichment designs. In this article, we summarize the developments over the past 25 years from different perspectives. We provide a historical overview of the early days, review the key methodological concepts and summarize regulatory and industry perspectives on such designs. Then, we illustrate the application of adaptive designs with three case studies, including unblinded sample size reassessment, adaptive treatment selection, and adaptive endpoint selection. We also discuss the availability of software for evaluating and performing such designs. We conclude with a critical review of how expectations from the beginning were fulfilled, and – if not – discuss potential reasons why this did not happen. © 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd.
‘Multistage testing with adaptive designs’ was the title of an article by Peter Bauer that appeared 1989 in the German journal Biometrie und Informatik in Medizin und Biologie . The journal does not exist anymore but the methodology found widespread interest in the scientific community over the past 25 years. The use of such multistage adaptive designs raised many controversial discussions from the beginning on, especially after the publication by Bauer and Köhne 1994 in Biometrics : Broad enthusiasm about potential applications of such designs faced critical positions regarding their statistical efficiency. Despite, or possibly because of, this controversy, the methodology and its areas of applications grew steadily over the years, with significant contributions from statisticians working in academia, industry and agencies around the world. In the meantime, such type of adaptive designs have become the subject of two major regulatory guidance documents in the US and Europe and the field is still evolving. Developments are particularly noteworthy in the most important applications of adaptive designs, including sample size reassessment, treatment selection procedures, and population enrichment designs. In this article, we summarize the developments over the past 25 years from different perspectives. We provide a historical overview of the early days, review the key methodological concepts and summarize regulatory and industry perspectives on such designs. Then, we illustrate the application of adaptive designs with three case studies, including unblinded sample size reassessment, adaptive treatment selection, and adaptive endpoint selection. We also discuss the availability of software for evaluating and performing such designs. We conclude with a critical review of how expectations from the beginning were fulfilled, and – if not – discuss potential reasons why this did not happen. © 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd.
'Multistage testing with adaptive designs' was the title of an article by Peter Bauer that appeared 1989 in the German journal Biometrie und Informatik in Medizin und Biologie. The journal does not exist anymore but the methodology found widespread interest in the scientific community over the past 25 years. The use of such multistage adaptive designs raised many controversial discussions from the beginning on, especially after the publication by Bauer and Köhne 1994 in Biometrics: Broad enthusiasm about potential applications of such designs faced critical positions regarding their statistical efficiency. Despite, or possibly because of, this controversy, the methodology and its areas of applications grew steadily over the years, with significant contributions from statisticians working in academia, industry and agencies around the world. In the meantime, such type of adaptive designs have become the subject of two major regulatory guidance documents in the US and Europe and the field is still evolving. Developments are particularly noteworthy in the most important applications of adaptive designs, including sample size reassessment, treatment selection procedures, and population enrichment designs. In this article, we summarize the developments over the past 25 years from different perspectives. We provide a historical overview of the early days, review the key methodological concepts and summarize regulatory and industry perspectives on such designs. Then, we illustrate the application of adaptive designs with three case studies, including unblinded sample size reassessment, adaptive treatment selection, and adaptive endpoint selection. We also discuss the availability of software for evaluating and performing such designs. We conclude with a critical review of how expectations from the beginning were fulfilled, and - if not - discuss potential reasons why this did not happen.
'Multistage testing with adaptive designs' was the title of an article by Peter Bauer that appeared 1989 in the German journal Biometrie und Informatik in Medizin und Biologie. The journal does not exist anymore but the methodology found widespread interest in the scientific community over the past 25 years. The use of such multistage adaptive designs raised many controversial discussions from the beginning on, especially after the publication by Bauer and Kohne 1994 in Biometrics: Broad enthusiasm about potential applications of such designs faced critical positions regarding their statistical efficiency. Despite, or possibly because of, this controversy, the methodology and its areas of applications grew steadily over the years, with significant contributions from statisticians working in academia, industry and agencies around the world. In the meantime, such type of adaptive designs have become the subject of two major regulatory guidance documents in the US and Europe and the field is still evolving. Developments are particularly noteworthy in the most important applications of adaptive designs, including sample size reassessment, treatment selection procedures, and population enrichment designs. In this article, we summarize the developments over the past 25 years from different perspectives. We provide a historical overview of the early days, review the key methodological concepts and summarize regulatory and industry perspectives on such designs. Then, we illustrate the application of adaptive designs with three case studies, including unblinded sample size reassessment, adaptive treatment selection, and adaptive endpoint selection. We also discuss the availability of software for evaluating and performing such designs. We conclude with a critical review of how expectations from the beginning were fulfilled, and -- if not -- discuss potential reasons why this did not happen.
Author Dragalin, Vladimir
König, Franz
Bauer, Peter
Wassmer, Gernot
Bretz, Frank
AuthorAffiliation 6 Institute for Medical Statistics, Informatics and Epidemiology University of Cologne 50924 Köln Germany
3 Shanghai University of Finance and Economics China
4 Johnson and Johnson 1400 McKean Rd, Spring House PA 19477 U.S.A
1 Section of Medical Statistics Medical University of Vienna Spitalgasse 23 1090 Wien Austria
2 Novartis Pharma AG Lichtstrasse 35 4002 Basel Switzerland
5 Aptiv Solutions, an ICON plc company Robert‐Perthel‐Str. 77a 50739 Köln Germany
AuthorAffiliation_xml – name: 3 Shanghai University of Finance and Economics China
– name: 1 Section of Medical Statistics Medical University of Vienna Spitalgasse 23 1090 Wien Austria
– name: 6 Institute for Medical Statistics, Informatics and Epidemiology University of Cologne 50924 Köln Germany
– name: 5 Aptiv Solutions, an ICON plc company Robert‐Perthel‐Str. 77a 50739 Köln Germany
– name: 2 Novartis Pharma AG Lichtstrasse 35 4002 Basel Switzerland
– name: 4 Johnson and Johnson 1400 McKean Rd, Spring House PA 19477 U.S.A
Author_xml – sequence: 1
  givenname: Peter
  surname: Bauer
  fullname: Bauer, Peter
  organization: Section of Medical Statistics, Medical University of Vienna, Spitalgasse 23, 1090 Wien, Austria
– sequence: 2
  givenname: Frank
  surname: Bretz
  fullname: Bretz, Frank
  organization: Novartis Pharma AG, Lichtstrasse 35, 4002, Basel, Switzerland
– sequence: 3
  givenname: Vladimir
  surname: Dragalin
  fullname: Dragalin, Vladimir
  organization: Johnson and Johnson, 1400 McKean Rd, Spring House, PA, 19477, U.S.A
– sequence: 4
  givenname: Franz
  surname: König
  fullname: König, Franz
  organization: Section of Medical Statistics, Medical University of Vienna, Spitalgasse 23, 1090 Wien, Austria
– sequence: 5
  givenname: Gernot
  surname: Wassmer
  fullname: Wassmer, Gernot
  email: Correspondence to: Gernot Wassmer, Institute for Medical Statistics, Informatics and Epidemiology, University of Cologne 50924 Köln, Germany., gernot.wassmer@uni-koeln.de
  organization: Aptiv Solutions, an ICON plc company, Robert-Perthel-Str. 77a, 50739, Köln, Germany
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25778935$$D View this record in MEDLINE/PubMed
BookMark eNp1kUFP3DAQha2KqixQqb-gitRLL9l6nMST9FAJoZZSUZDKSpW4WI7jUNPETm0HyL8nK2ALqD3NYb55M2_eDtmyzmpC3gBdAqXsQzD9kufIXpAF0ApTyopyiywoQ0w5QrFNdkK4pBSgYPiKbLMCsayyYkFOVtfaxiltzZVOJi19SFybKGdb43sZnZ8S2cghrtuNDubCho-JGwbn42hNNDok0jbJYGIruy7skZdzDfr1fd0lZ18-rw6-psenh0cH-8ep4sBYWjKoZZXrTCNkWraSSdaoJi-Q14xlVEGLNaBqG6wVA97SSqEqcw0Ulcx2yac71WGse92o2YGXnRi86aWfhJNGPO1Y80tcuCvBeUmhglng_b2Ad39GHaLoTVC666TVbgwCkNOKZlVZzui7Z-ilG72dzc1UUQHPocpn6u3jizanPDz670blXQhetxsEqFhnKOYMxTrDGV0-Q5WJMhq39mK6fw2kdwPXptPTf4XF2dH3p7wJUd9seOl_C44ZFuLnyaFYfaPn-IOeC57dAoN8vWY
CODEN SMEDDA
CitedBy_id crossref_primary_10_1016_j_jclinepi_2018_02_013
crossref_primary_10_1097_PR9_0000000000000863
crossref_primary_10_1186_s12874_020_01169_7
crossref_primary_10_1016_j_cct_2017_04_005
crossref_primary_10_1186_s12916_020_01808_2
crossref_primary_10_1016_S2214_109X_20_30539_8
crossref_primary_10_1053_j_jvca_2018_02_009
crossref_primary_10_1016_j_jclinepi_2020_09_019
crossref_primary_10_1002_pst_2122
crossref_primary_10_1071_MA19004
crossref_primary_10_3389_fncel_2022_977679
crossref_primary_10_1016_S1441_2772_23_00939_0
crossref_primary_10_1002_sim_6797
crossref_primary_10_1002_pst_1951
crossref_primary_10_1002_sim_8291
crossref_primary_10_1177_1740774516689261
crossref_primary_10_1016_j_cct_2021_106397
crossref_primary_10_1186_s12874_024_02293_4
crossref_primary_10_1016_j_foodqual_2025_105523
crossref_primary_10_1016_j_jacbts_2019_02_005
crossref_primary_10_1080_19466315_2017_1422799
crossref_primary_10_1186_s13063_021_05130_x
crossref_primary_10_1002_sim_7936
crossref_primary_10_1111_jcpt_12617
crossref_primary_10_1002_pst_2190
crossref_primary_10_1177_2168479017706526
crossref_primary_10_1186_s13023_018_0820_8
crossref_primary_10_1371_journal_pone_0231241
crossref_primary_10_1002_eat_24167
crossref_primary_10_1080_00031305_2021_1901782
crossref_primary_10_1002_pst_1942
crossref_primary_10_1016_j_softx_2023_101347
crossref_primary_10_1371_journal_pone_0269369
crossref_primary_10_1002_cpt_2575
crossref_primary_10_1002_pst_1926
crossref_primary_10_1002_sim_10310
crossref_primary_10_1038_s41393_020_00547_8
crossref_primary_10_1007_s40256_021_00480_y
crossref_primary_10_1093_biostatistics_kxw012
crossref_primary_10_1002_sim_9288
crossref_primary_10_3390_stats4040062
crossref_primary_10_1136_bmj_m115
crossref_primary_10_1002_bimj_201900020
crossref_primary_10_1002_pst_2066
crossref_primary_10_1177_0962280219862313
crossref_primary_10_1186_s13063_023_07398_7
crossref_primary_10_1002_pst_2228
crossref_primary_10_1002_bimj_202100166
crossref_primary_10_1002_cpt_515
crossref_primary_10_1080_10543406_2020_1832110
crossref_primary_10_1002_ajp_23331
crossref_primary_10_1016_j_drudis_2017_10_012
crossref_primary_10_1177_2168479016667766
crossref_primary_10_1080_19466315_2018_1560359
crossref_primary_10_2196_medinform_8207
crossref_primary_10_1080_19466315_2022_2063171
crossref_primary_10_1016_j_cct_2024_107560
crossref_primary_10_1016_j_conctc_2023_101220
crossref_primary_10_1371_journal_pone_0163726
crossref_primary_10_1016_S1473_3099_24_00769_2
crossref_primary_10_1002_pst_1762
crossref_primary_10_1002_sim_9734
crossref_primary_10_1002_sim_9339
crossref_primary_10_1177_2168479019825634
crossref_primary_10_1177_2168479018807715
crossref_primary_10_1007_s43441_024_00676_9
crossref_primary_10_1214_20_AOS1978
crossref_primary_10_1093_biostatistics_kxac040
crossref_primary_10_1056_NEJMra1510061
crossref_primary_10_1080_17512433_2017_1321985
crossref_primary_10_1177_0962280217747312
crossref_primary_10_1186_s13063_015_1119_x
crossref_primary_10_1002_sim_10130
crossref_primary_10_3390_s23020875
crossref_primary_10_1002_sim_8939
crossref_primary_10_1136_bmjopen_2022_069430
crossref_primary_10_1177_1740774517699406
crossref_primary_10_1016_j_cjca_2021_06_023
crossref_primary_10_1093_ecco_jcc_jjae026
crossref_primary_10_1002_pst_2168
crossref_primary_10_1080_19466315_2017_1323670
crossref_primary_10_1002_sim_7200
crossref_primary_10_1016_S2214_109X_20_30540_4
crossref_primary_10_1186_s12874_019_0800_2
crossref_primary_10_1177_0023677220907617
crossref_primary_10_1186_s13063_018_3012_x
crossref_primary_10_1186_s12874_023_02024_1
crossref_primary_10_1002_pst_1753
crossref_primary_10_1002_pst_1873
crossref_primary_10_1080_19466315_2025_2455173
crossref_primary_10_1186_s40249_022_01031_6
crossref_primary_10_1093_cid_cix907
crossref_primary_10_1016_j_cct_2020_106215
crossref_primary_10_1186_s13063_019_3708_6
crossref_primary_10_1016_j_critrevonc_2024_104402
crossref_primary_10_1186_s12916_018_1196_2
crossref_primary_10_1186_s13063_020_04334_x
crossref_primary_10_1002_sim_8949
crossref_primary_10_1016_j_jclinepi_2022_12_010
crossref_primary_10_1002_sim_70045
crossref_primary_10_1002_sim_8543
crossref_primary_10_1111_all_15945
crossref_primary_10_1002_sim_7851
crossref_primary_10_1080_10543406_2024_2342518
crossref_primary_10_1057_s41270_022_00177_4
crossref_primary_10_1186_s12874_022_01678_7
crossref_primary_10_1080_19466315_2020_1790415
crossref_primary_10_3389_fphar_2025_1548997
crossref_primary_10_3389_fpsyt_2024_1217102
crossref_primary_10_1002_bimj_201700281
crossref_primary_10_1080_03610926_2018_1543770
crossref_primary_10_1186_s12916_018_1017_7
crossref_primary_10_2214_AJR_20_22852
crossref_primary_10_1093_biostatistics_kxw054
crossref_primary_10_5691_jjb_43_37
crossref_primary_10_1002_sim_8034
crossref_primary_10_1002_sim_8430
crossref_primary_10_1002_sim_8953
crossref_primary_10_1002_bimj_201500077
crossref_primary_10_1186_s13063_020_04931_w
crossref_primary_10_1080_10543406_2019_1632871
crossref_primary_10_1016_j_softx_2023_101515
crossref_primary_10_1080_10543406_2023_2233590
crossref_primary_10_12688_gatesopenres_12912_2
crossref_primary_10_12688_gatesopenres_12912_1
crossref_primary_10_1002_sim_7910
crossref_primary_10_1007_s10683_022_09773_8
crossref_primary_10_1007_s12561_017_9188_x
crossref_primary_10_1002_sim_6823
crossref_primary_10_1016_j_ejca_2023_113278
crossref_primary_10_1080_02664763_2024_2342424
crossref_primary_10_1016_j_clinthera_2020_05_010
crossref_primary_10_1007_s00103_019_02955_5
crossref_primary_10_1186_s13063_023_07654_w
crossref_primary_10_1002_1878_0261_12465
crossref_primary_10_1002_sim_10090
crossref_primary_10_1177_1740774517724746
crossref_primary_10_1080_10543406_2023_2204943
crossref_primary_10_1177_1740774516643689
crossref_primary_10_1371_journal_pone_0180131
crossref_primary_10_1080_10543406_2023_2183962
Cites_doi 10.1002/sim.3863
10.1177/009286150103500407
10.1002/sim.3048
10.1111/j.1541-0420.2008.01101.x
10.1002/sim.734
10.1164/rccm.200910-1500OC
10.1111/j.1541-0420.2008.01174.x
10.1177/216847900604000408
10.1002/sim.5377
10.1016/0197-2456(87)90039-0
10.1002/bimj.200390001
10.1002/bimj.200390051
10.1002/(SICI)1097-0258(20000415)19:7<901::AID-SIM405>3.0.CO;2-L
10.1002/sim.1457
10.1198/016214502388618852
10.2307/3109775
10.1080/10543406.2014.925911
10.1002/sim.3436
10.1093/bioinformatics/btm140
10.1080/10543400600614742
10.1093/biomet/93.1.1
10.1002/bimj.200510231
10.1002/sim.2258
10.1097/PCC.0000000000000151
10.1002/sim.6407
10.1002/pst.206
10.1002/sim.2389
10.1016/S0378-3758(99)00032-4
10.1016/S0735-1097(01)01608-4
10.1080/10543406.2011.554129
10.1177/216847900604000409
10.1002/sim.1688
10.1002/sim.2957
10.1002/1521-4036(200111)43:7<821::AID-BIMJ821>3.0.CO;2-F
10.1002/sim.3062
10.1080/01621459.2012.682540
10.1080/10543406.2014.931409
10.1002/047005588X
10.1080/10543406.2011.551336
10.1002/pst.472
10.1002/sim.4202
10.1016/S0197-2456(00)00122-7
10.1177/009286150003400227
10.1002/sim.972
10.1002/(SICI)1097-0258(19980730)17:14<1551::AID-SIM868>3.0.CO;2-E
10.1002/sim.3716
10.1002/sim.3538
10.1080/10543400701645439
10.1002/sim.6192
10.1016/S0197-2456(97)00075-5
10.1002/sim.2966
10.1002/sim.6288
10.1111/j.1541-0420.2010.01507.x
10.32614/CRAN.package.adaptTest
10.1111/j.0006-341X.2001.00886.x
10.1002/(SICI)1521-4036(199906)41:3<261::AID-BIMJ261>3.0.CO;2-U
10.1002/sim.1455
10.1093/biomet/ast035
10.1002/bimj.200510232
10.1186/1745-6215-15-383
10.1002/sim.4780140922
10.1002/(SICI)1521-4036(199910)41:6<689::AID-BIMJ689>3.0.CO;2-P
10.1136/jnnp-2012-302468
10.1002/sim.5361
10.1080/01621459.2011.644141
10.1002/sim.4424
10.1007/978-1-4939-1100-4_8
10.1016/j.jspi.2005.08.014
10.2307/2684438
10.1016/S1359-6446(04)03023-5
10.1002/sim.1136
10.1002/sim.4179
10.1002/sim.4780132309
10.1002/pst.300
10.1002/bimj.200510190
10.1002/sim.5847
10.1002/sim.3704
10.1002/bimj.201300257
10.1080/10543400701645405
10.2307/2531158
10.1038/nrd3079
10.1007/978-3-0348-0709-8_5
10.1002/sim.6272
10.1002/sim.3495
10.1016/j.jspi.2005.08.015
10.1093/biomet/63.3.655
10.1201/EBK1439825488
10.1002/sim.3513
10.1002/sim.6183
10.1177/009286150904300503
10.1002/bimj.201200218
10.1002/sim.1852
10.1002/sim.2180
10.1080/10543406.2013.857238
10.2307/2533262
10.1093/biomet/90.2.367
10.1002/pst.302
10.1002/sim.3559
10.1038/nrd4319
10.1111/j.0006-341X.2004.00246.x
10.1002/sim.5541
10.1111/j.1541-0420.2006.00626.x
10.1111/j.0006-341X.1999.00853.x
10.1002/bimj.200510311
10.1080/19466315.2013.791639
10.1016/j.cct.2013.09.008
10.1002/sim.531
10.1177/2168479013486996
10.1002/sim.1362
10.1177/2168479014522468
10.1002/ddr.20285
10.1007/978-1-4939-1100-4_14
10.1002/pst.1640
10.1002/sim.2251
10.1002/bimj.200510238
10.1002/sim.2725
10.1080/03610929208830947
10.1198/016214502753479374
10.1080/10543400701645215
10.1002/sim.4780110107
10.1002/bimj.200510233
10.1002/sim.5977
10.1002/pst.413
10.2307/2533441
10.1002/bimj.200900003
10.1002/sim.4102
10.1002/(SICI)1097-0258(19990730)18:14<1833::AID-SIM221>3.0.CO;2-3
10.1002/bimj.4710310600
10.1002/1521-4036(200109)43:5<581::AID-BIMJ581>3.0.CO;2-J
10.1002/bimj.200900207
10.1002/bimj.201200245
10.1056/NEJMoa1404710
10.1016/j.pupt.2010.01.003
10.1111/j.0006-341X.1999.01286.x
10.1177/009286159302700314
10.1198/tast.2011.10213
10.1177/216847900604000412
10.1002/bimj.200710453
10.1161/CIRCULATIONAHA.108.809707
10.1111/j.0006-341X.2004.00221.x
10.1002/sim.1759
10.1016/j.cct.2008.12.002
10.1080/10543406.2014.920869
10.1002/bimj.201000239
10.1002/(SICI)1521-4036(199906)41:3<279::AID-BIMJ279>3.0.CO;2-V
10.2307/2532142
10.1002/bimj.200810442
10.1002/bimj.201300153
10.1002/bimj.200410042
10.1002/sim.4780090113
ContentType Journal Article
Copyright 2015 The Authors. Published by John Wiley & Sons Ltd.
2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd.
Copyright Wiley Subscription Services, Inc. Feb 10, 2016
Copyright_xml – notice: 2015 The Authors. Published by John Wiley & Sons Ltd.
– notice: 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd.
– notice: Copyright Wiley Subscription Services, Inc. Feb 10, 2016
DBID BSCLL
24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
K9.
7X8
5PM
DOI 10.1002/sim.6472
DatabaseName Istex
Wiley Online Library Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef

MEDLINE - Academic

MEDLINE
ProQuest Health & Medical Complete (Alumni)
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Statistics
Public Health
DocumentTitleAlternate P. BAUER ET AL
EISSN 1097-0258
EndPage 347
ExternalDocumentID PMC6680191
3930435301
25778935
10_1002_sim_6472
SIM6472
ark_67375_WNG_TJ0Z7R0Z_6
Genre article
Research Support, Non-U.S. Gov't
Journal Article
Feature
GeographicLocations United States--US
Europe
GeographicLocations_xml – name: Europe
– name: United States--US
GroupedDBID ---
.3N
.GA
05W
0R~
10A
123
1L6
1OB
1OC
1ZS
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5RE
5VS
66C
6PF
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAWTL
AAXRX
AAZKR
ABCQN
ABCUV
ABIJN
ABJNI
ABOCM
ABPVW
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACPOU
ACXBN
ACXQS
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AHMBA
AITYG
AIURR
AIWBW
AJBDE
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ATUGU
AUFTA
AZBYB
AZVAB
BAFTC
BFHJK
BHBCM
BMNLL
BMXJE
BNHUX
BROTX
BRXPI
BSCLL
BY8
CS3
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRSTM
DU5
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
G-S
G.N
GNP
GODZA
H.T
H.X
HBH
HGLYW
HHY
HHZ
HZ~
IX1
J0M
JPC
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MXFUL
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
P2P
P2W
P2X
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
ROL
RWI
RX1
RYL
SUPJJ
SV3
TN5
UB1
V2E
W8V
W99
WBKPD
WH7
WIB
WIH
WIK
WJL
WOHZO
WQJ
WRC
WUP
WWH
WXSBR
WYISQ
XBAML
XG1
XV2
ZZTAW
~IA
~WT
24P
AAHQN
AAMNL
AAYCA
ACYXJ
AFWVQ
ALVPJ
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
AMVHM
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
K9.
7X8
5PM
AANHP
ACRPL
ADNMO
ID FETCH-LOGICAL-c6122-821ba94e3e713eafa2a2dcd4576b2230c1f7b17cfd7bc216f09c7c84e107ca3
IEDL.DBID DR2
ISSN 0277-6715
IngestDate Thu Aug 21 18:31:39 EDT 2025
Fri Jul 11 05:38:01 EDT 2025
Sun Jul 13 04:01:15 EDT 2025
Thu Apr 03 06:52:54 EDT 2025
Tue Jul 01 04:46:06 EDT 2025
Thu Apr 24 23:10:55 EDT 2025
Wed Jan 22 16:38:37 EST 2025
Wed Oct 30 09:52:31 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords group sequential designs
clinical trials
adaptive design
Language English
License Attribution-NonCommercial
http://creativecommons.org/licenses/by-nc/4.0
2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd.
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c6122-821ba94e3e713eafa2a2dcd4576b2230c1f7b17cfd7bc216f09c7c84e107ca3
Notes istex:E1420A566AD506D638656D0F28A887F9AE0285CE
ArticleID:SIM6472
ark:/67375/WNG-TJ0Z7R0Z-6
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-2008-8340
OpenAccessLink https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fsim.6472
PMID 25778935
PQID 1759164194
PQPubID 48361
PageCount 23
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6680191
proquest_miscellaneous_1760903988
proquest_journals_1759164194
pubmed_primary_25778935
crossref_primary_10_1002_sim_6472
crossref_citationtrail_10_1002_sim_6472
wiley_primary_10_1002_sim_6472_SIM6472
istex_primary_ark_67375_WNG_TJ0Z7R0Z_6
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 10 February 2016
PublicationDateYYYYMMDD 2016-02-10
PublicationDate_xml – month: 02
  year: 2016
  text: 10 February 2016
  day: 10
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: New York
– name: Hoboken
PublicationTitle Statistics in medicine
PublicationTitleAlternate Statist. Med
PublicationYear 2016
Publisher Blackwell Publishing Ltd
Wiley Subscription Services, Inc
John Wiley and Sons Inc
Publisher_xml – name: Blackwell Publishing Ltd
– name: Wiley Subscription Services, Inc
– name: John Wiley and Sons Inc
References Gao P, Liu L, Mehta C. Exact inference for adaptive group sequential designs. Statistics in Medicine 2013; 32(23):3991-4005.
Wassmer G. On sample size determination in multi-armed confirmatory adaptive designs. Journal of Biopharmaceutical Statistics 2011; 21:802-817.
Bowden J, Glimm E. Unbiased estimation of selected treatment means in two-stage trials. Biometrical Journal 2008; 50(4):515-527.
Mehta CR, Tsiatis AA. Flexible sample size considerations using information-based interim monitoring. Drug Information Journal 2001; 35:1095-1112.
Brannath W, Mehta CR, Posch M. Exact confidence bounds following adaptive group sequential tests. Biometrics 2009; 65(2):539-546.
Magirr D, Jaki T, Koenig F, Posch M. Adaptive survival trials. arXiv preprint arXiv:1405.1569 2014.
Irle S, Schäfer H. Interim design modificcations in time-to-event studies. Journal of the American Statistical Association 2014; 107:341-348.
Schneider S, Schmidli H, Friede T. Blinded sample size re-estimation for recurrent event data with time trends. Statistics in Medicine 2013; 32(30):5448-5457.
Bauer P. Multistage testing with adaptive designs. Biometrie und Informatik in Medizin und Biologie 1989; 20:130-148.
Proschan M, Glimm E, Posch M. Connections between permutation and t-tests: relevance to adaptive methods. Statistics in Medicine 2014; 33(27):4734-4742.
Magirr D, Jaki T, Posch M, Klinglmüller F. Simultaneous confidence intervals that are compatible with closed testing in adaptive designs. Biometrika 2013; 100(4):985-996.
Stallard N, Todd S. Sequential designs for phase III clinical trials incorporating treatment selection. Statistics in Medicine 2003; 22(5):689-703.
Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. Academic Press: New York, 1985.
Denne JS. Sample size recalculation using conditional power. Statistics in Medicine 2001; 20:2645-2660.
König F, Brannath W, Bretz F, Posch M. Adaptive Dunnett tests for treatment selection. Statistics in Medicine 2008; 27:1612-1625.
Timmesfeld N, Schäfer H, Müller H-H. Increasing the sample size during clinical trials with t-distributed test statistics without inflating the type I error rate. Statistics in Medicine 2007; 26(12):2449-2464.
Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics 1999; 55(4):1286-1290.
Phillips AJ, Keene ON. Adaptive designs for pivotal trials: discussion points from the PSI adaptive design expert group. Pharmaceutical Statistics 2006; 5(1):61-66.
Schmidli H, Bretz F, Racine-Poon A. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint. Statistics in Medicine 2007; 26(27):4925-4938.
Burman C-F, Sonesson C. Are flexible designs sound? Biometrics 2006; 62(3):664-669.
FDA. Draft Guidance for Industry Adaptive Design Clinical Trials for Drugs and Biologics. Food and Drug Administration. Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER): Rockville MD, USA, 2010. url=http://http://www.fda.gov/.
Gutjahr G, Brannath W, Bauer P. An approach to the conditional error rate principle with nuisance parameters. Biometrics 2011; 67(3):1039-1046.
Goll A, Bauer P. Two-stage designs applying methods differing in costs. Bioinformatics 2007; 23(12):1519-1526.
Chuang-Stein C, Bretz F, Komiyama O, Quinlan J. Interactions with regulatory agencies to enhance the understanding and acceptance of adaptive designs. Regulatory Affairs Focus 2009; 14(4):36-42.
Elsäßer A, Regnstrom J, Vetter T, Koenig F, Hemmings RJ, Greco M, Papaluca-Amati M, Posch M. Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency. Trials 2014; 15(1):383.
Coburger S, Wassmer G. Conditional point estimation in adaptive group sequential test designs. Biometrical Journal 2001; 43(7):821-833.
Brannath W, König F, Bauer P. Estimation in flexible two stage designs. Statistics in Medicine 2006; 25(19):3366-3381.
Brannath W, Bauer P, Posch M. On the efficiency of adaptive designs for flexible interim decisions in clinical trials. Journal of Statistical Planning and Inference 2006; 136(6):1956-1961.
Müller HH, Schäfer H. A general statistical principle for changing a design any time during the course of a trial. Statistics in Medicine 2004; 23:2497-2508.
Graf A, Posch M, Koenig F. Adaptive designs for subpopulation analysis optimizing utility functions. Biometrical Journal 2015; 57(1):76-89.
Barnes PJ, Pocock SJ, Magnussen H. Integrating indacaterol dose selection in a clinical study in copd using an adaptive seamless design. Pulmonary Pharmacology & Therapeutics 2010; 23:165-171.
Dragalin V. Adaptive designs: Terminology and classification. Drug Information Journal 2006; 40:425-435.
Hünseler C, Balling G, Röhlig C, Blickheuser R, Trieschmann U, Lieser U, Dohna-Schwake C, Gebauer C, Möller O, Hering F, Hoehn T., Schubert S, Hentschel R, Huth RG, Müller A, Müller C, Wassmer G, Hahn M, Harnischmacher U, Behr J, Roth B. Continuous infusion of clonidine in ventilated newborns and infants: A randomized controlled trial. Pediatric Critical Care Medicine 2014; 15:511-522.
Lehmacher W, Kieser M, Hothorn L. Sequential and multiple testing for dose-response analysis. Drug Information Journal 2000; 34:591-597.
PhRMA Working Group on Adaptive Designs. White papers. Drug Information Journal 2006; 40(22):421-484.
Bauer P, Brannath W. The advantages and disadvantages of adaptive designs for clinical trials. Drug Discovery Today 2004; 9:351-357.
Müller H-H, Schäfer H. Adaptive group sequential designs for clinical trials: Combining the advantages of adaptive and of classical group sequential approaches. Biometrics 2001; 57:886-891.
Hung HMJ, Wang S-J, Yang P. Some challenges with statistical inference in adaptive designs. Journal of Biopharmaceutical Statistics 2014; 24(5):1059-1072.
Bowden J, Glimm E. Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop-the-losers trials. Biometrical Journal 2014; 56(2):332-349.
Lawrence J, Hung HM. Estimation and confidence intervals after adjusting the maximum information. Biometrical Journal 2003; 45(2):143-152.
Wassmer G, Reitmeir P, Kieser M, Lehmacher W. Procedures for testing multiple endpoints in clinical trials: An overview. Journal of Statistical Planning and Inference 1999; 82:69-81.
Tsiatis AA, Mehta C. On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika 2003; 90:367-378.
Bauer J, Einfalt P. Application of adaptive designs - a review. Biometrical Journal 2006; 8:1-16.
Quinlan JA, Krams M. Implementing adaptive designs: logistical and operational considerations. Drug Information Journal 2006; 40:437-444.
Mehta C, Gao P, Bhatt DL, Harrington RA, Skerjanec S, Ware JH. Optimizing trial design sequential, adaptive, and enrichment strategies. Circulation 2009; 119(4):597-605.
Wassmer G, Dragalin V. Designing issues in confirmatory adaptive population enrichment trials. Journal of Biopharmaceutical Statistics 2015; 25:early view.
Marcus R, Peritz E, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976; 63:655-660.
Scherag A, Hebebrand J, Schäfer H, Müller H-H. Flexible designs for genomewide association studies. Biometrics 2009; 65(3):815-821.
Proschan M, Lan G, Wittes J. Statistical Monitoring of Clinical Trials. A Unified Approach. Springer: Science & Business Media, 2006.
Klinglmueller F, Posch M, Koenig F. Adaptive graph-based multiple testing procedures. Pharmaceutical Statistics 2014; 13(6):345-356.
Gould AL. Planning and revising the sample size for a trial. Statistics in Medicine 1995; 14:1039-1051.
Cui L, Hung HMJ, Wang S-J. Modification of sample size in group sequential clinical trials. Biometrics 1999; 55:853-857.
Wassmer G. A comparison of two methods for adaptive interim analyses in clinical trials. Biometrics 1998; 54:696-705.
Stallard N, Hamborg T, Parsons N, Friede T. Adaptive designs for confirmatory clinical trials with subgroup selection. Journal of Biopharmaceutical Statistics 2014; 24(1):168-187.
Emerson SS. Statistical packages for group sequential methods. The American Statistician 1996; 50:183-192.
Mehta CR, Pocock SJ. Adaptive increase in sample size when interim results are promising: A practical guide with examples. Statistics in Medicine 2011; 30(28):3267-3284.
Faldum A, Hommel G. Strategies for including patients recruited during interim analysis of clinical trials. Journal of Biopharmaceutical Statistics 2007; 17(6):1211-1225.
Desseaux K, Porcher R. Flexible two-stage design with sample size reassessment for survival trials. Statistics in Medicine 2007; 26(27):5002-5013.
Hartung J. A self-designing rule for clinical trials with arbitrary variables. Controlled Clinical Trials 2001; 22:111-116.
Wang S-J, Brannath W, Brückner M, James Hung HM, Koch A. Unblinded adaptive statistical information design based on clinical endpoint or biomarker. Statistics in Biopharmaceutical Research 2013; 5(4):293-310.
Graf AC, Bauer P, Glimm E, Koenig F. Maximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications. Biometrical Journal 2014; 56(4):614-630.
O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics 1984; 40:1079-1087.
Chang M. Adaptive Design Theory and Implementation Using SAS and R. Chapman and Hall/CRC: Boca Raton, London, New York, 2008.
Antonijevic Z, Gallo G, Chuang-Stein C, Dragalin V, Loewy J, Menon S, Miller ER, CC Morgan, Sanchez M. Views on emerging issues pertaining to data monitoring committees for adaptive trials. Therapeutic Innovation & Regulatory Science 2013; 47:495-502.
Brannath W, Gutjahr G, Bauer P. Probabilistic foundation of confirmatory adaptive designs. Journal of the American Statistical Association 2012; 107:824-832.
Bauer P, Köhne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994; 50:1029-1041, correc
1976; 63
1993; 27
2002; 97
2015; 72
2004; 23
2004; 9
2011; 53
2014; 24
1999; 41
2014; Accepted
2010; 182
2009; 119
2013; 5
2005; 2443
2001; 43
2010; 23
2009; 14
1998; 17
2000; 19
1989; 31
2013; 55
2010; 29
2015; Early View
2006; 25
2008; 27
2014; 15
1999; 55
1985
2007; 6
2014; 13
2011; 65
2011; 67
2001; 57
2010; 9
2003; 45
2007; 17
2015; 57
1984; 40
1995; 51
2009; 65
2004; 46
1998
2013; 100
2014; 48
2001; 22
2008; 50
2012; 107
2012; 31
2001; 20
1999
2006; 40
2009; 70
2006; 48
1994; 13
2001; 38
1992; 21
1990; 9
2001; 35
2010; 52
2014; 33
2003; 22
2009; 43
2004; 60
1987; 8
2011; 10
1999; 82
1992; 11
2006; 136
2003; 90
2009; 51
2014; 3
1991; 47
2006; 62
2000
1999; 18
1997; 18
2011; 21
1998; 54
2007; 23
2014; 56
2007; 26
2012; 83
2006; 93
2013; 47
1989; 20
2012
2010
1995; 14
2006; 16
1996; 50
2009
2011; 30
2006; 8
2008
2007
2006; 5
2006
2009; 28
2014; 107
2015; 25
2009; 30
2013; 36
2013; 32
2000; 34
2015
2014
2013
1994; 50
2007; 49
e_1_2_9_75_1
e_1_2_9_98_1
e_1_2_9_52_1
e_1_2_9_79_1
Heritier S (e_1_2_9_146_1) 2015
e_1_2_9_94_1
e_1_2_9_10_1
e_1_2_9_56_1
e_1_2_9_33_1
e_1_2_9_90_1
e_1_2_9_71_1
e_1_2_9_126_1
e_1_2_9_149_1
e_1_2_9_107_1
e_1_2_9_122_1
e_1_2_9_145_1
e_1_2_9_168_1
e_1_2_9_14_1
Lawrence D (e_1_2_9_142_1) 2014
e_1_2_9_37_1
e_1_2_9_164_1
e_1_2_9_18_1
e_1_2_9_160_1
e_1_2_9_41_1
e_1_2_9_64_1
e_1_2_9_87_1
e_1_2_9_22_1
e_1_2_9_45_1
e_1_2_9_68_1
e_1_2_9_83_1
Carreras M (e_1_2_9_103_1) 2015
e_1_2_9_6_1
e_1_2_9_119_1
e_1_2_9_60_1
e_1_2_9_138_1
e_1_2_9_111_1
Hedges LV (e_1_2_9_35_1) 1985
e_1_2_9_134_1
e_1_2_9_115_1
e_1_2_9_157_1
e_1_2_9_26_1
e_1_2_9_49_1
e_1_2_9_130_1
e_1_2_9_176_1
e_1_2_9_153_1
e_1_2_9_172_1
e_1_2_9_30_1
e_1_2_9_53_1
e_1_2_9_99_1
Chang M (e_1_2_9_167_1) 2008
e_1_2_9_72_1
e_1_2_9_11_1
e_1_2_9_34_1
e_1_2_9_57_1
e_1_2_9_95_1
Chuang‐Stein C (e_1_2_9_132_1) 2009; 14
e_1_2_9_76_1
PhRMA Working Group on Adaptive Designs (e_1_2_9_131_1) 2006; 40
e_1_2_9_102_1
e_1_2_9_148_1
e_1_2_9_129_1
e_1_2_9_144_1
e_1_2_9_125_1
e_1_2_9_15_1
e_1_2_9_38_1
e_1_2_9_140_1
e_1_2_9_163_1
e_1_2_9_121_1
e_1_2_9_19_1
e_1_2_9_88_1
e_1_2_9_61_1
e_1_2_9_46_1
e_1_2_9_84_1
Bauer P (e_1_2_9_2_1) 1989; 20
e_1_2_9_23_1
e_1_2_9_65_1
Tymofyeyev Y (e_1_2_9_156_1) 2014
e_1_2_9_80_1
e_1_2_9_5_1
e_1_2_9_114_1
e_1_2_9_137_1
Sugitani T (e_1_2_9_91_1) 2014
e_1_2_9_118_1
e_1_2_9_179_1
e_1_2_9_9_1
e_1_2_9_175_1
e_1_2_9_27_1
e_1_2_9_69_1
Magirr D (e_1_2_9_100_1) 2014
e_1_2_9_110_1
e_1_2_9_171_1
Bauer J (e_1_2_9_133_1) 2006; 8
Gallo P (e_1_2_9_141_1) 2014
e_1_2_9_31_1
e_1_2_9_50_1
e_1_2_9_73_1
Jennison C (e_1_2_9_105_1) 2000
e_1_2_9_77_1
e_1_2_9_96_1
e_1_2_9_12_1
Wassmer G (e_1_2_9_42_1) 1999
e_1_2_9_54_1
e_1_2_9_92_1
e_1_2_9_109_1
EMA (e_1_2_9_7_1) 2007
Bauer P (e_1_2_9_36_1) 1989; 31
Proschan M (e_1_2_9_106_1) 2006
e_1_2_9_101_1
e_1_2_9_128_1
e_1_2_9_166_1
e_1_2_9_39_1
e_1_2_9_162_1
e_1_2_9_120_1
e_1_2_9_16_1
e_1_2_9_58_1
e_1_2_9_20_1
e_1_2_9_62_1
e_1_2_9_89_1
e_1_2_9_24_1
e_1_2_9_43_1
e_1_2_9_66_1
e_1_2_9_85_1
Chen JJ (e_1_2_9_124_1) 2014; 3
e_1_2_9_81_1
e_1_2_9_4_1
e_1_2_9_113_1
e_1_2_9_159_1
e_1_2_9_117_1
e_1_2_9_155_1
e_1_2_9_136_1
e_1_2_9_178_1
e_1_2_9_151_1
e_1_2_9_28_1
e_1_2_9_47_1
e_1_2_9_174_1
e_1_2_9_170_1
e_1_2_9_74_1
e_1_2_9_51_1
e_1_2_9_78_1
Chaturvedi PR (e_1_2_9_147_1) 2014
e_1_2_9_13_1
e_1_2_9_32_1
e_1_2_9_55_1
e_1_2_9_97_1
Lawrence D (e_1_2_9_143_1) 2014
e_1_2_9_93_1
e_1_2_9_108_1
e_1_2_9_70_1
e_1_2_9_127_1
e_1_2_9_123_1
e_1_2_9_169_1
FDA (e_1_2_9_8_1) 2010
e_1_2_9_104_1
e_1_2_9_17_1
e_1_2_9_59_1
e_1_2_9_165_1
e_1_2_9_161_1
e_1_2_9_180_1
EMA (e_1_2_9_152_1) 2006
e_1_2_9_40_1
e_1_2_9_21_1
e_1_2_9_67_1
e_1_2_9_44_1
e_1_2_9_86_1
e_1_2_9_82_1
e_1_2_9_3_1
Posch M (e_1_2_9_63_1) 2005; 2443
e_1_2_9_112_1
e_1_2_9_139_1
e_1_2_9_116_1
e_1_2_9_135_1
e_1_2_9_158_1
e_1_2_9_177_1
e_1_2_9_25_1
e_1_2_9_154_1
e_1_2_9_173_1
e_1_2_9_48_1
e_1_2_9_29_1
e_1_2_9_150_1
26757956 - Stat Med. 2016 Feb 10;35(3):364-7
26757952 - Stat Med. 2016 Feb 10;35(3):348-9
26757953 - Stat Med. 2016 Feb 10;35(3):350-8
26757955 - Stat Med. 2016 Feb 10;35(3):362-3
26757954 - Stat Med. 2016 Feb 10;35(3):359-61
References_xml – reference: Bretz F, Schmidli H, König F, Racine A, Maurer W. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: General concepts. Biometrical Journal 2006; 48(4):623-634.
– reference: Cheng Y, Shen Y. Estimation of a parameter and its exact confidence interval following sequential sample size reestimation trials. Biometrics 2004; 60(4):910-918.
– reference: Goll A, Bauer P. Two-stage designs applying methods differing in costs. Bioinformatics 2007; 23(12):1519-1526.
– reference: Wassmer G, Dragalin V. Designing issues in confirmatory adaptive population enrichment trials. Journal of Biopharmaceutical Statistics 2015; 25:early view.
– reference: Proschan M, Glimm E, Posch M. Connections between permutation and t-tests: relevance to adaptive methods. Statistics in Medicine 2014; 33(27):4734-4742.
– reference: PhRMA Working Group on Adaptive Designs. White papers. Drug Information Journal 2006; 40(22):421-484.
– reference: Jennison C, Turnbull BW. Adaptive and nonadaptive group sequential tests. Biometrika 2006; 93:1-21.
– reference: Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG, MUSEC Research Group. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. Journal of Neurology Neurosurgery and Psychiatry 2012; 83(11):1125-1132.
– reference: Bauer P, König F. The reassessment of trial perspectives from interim data - a critical view. Statistics In Medicine 2006; 25:23-36.
– reference: Hartung J. A self-designing rule for clinical trials with arbitrary variables. Controlled Clinical Trials 2001; 22:111-116.
– reference: Bauer P, Köhne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994; 50:1029-1041, correction in Biometrics 1996, 52:380.
– reference: Kieser M, Friede T. Re-calculating the sample size in internal pilot study designs with control of the type I error rate. Statistics in Medicine 2000; 19:901-911.
– reference: Gutjahr G, Brannath W, Bauer P. An approach to the conditional error rate principle with nuisance parameters. Biometrics 2011; 67(3):1039-1046.
– reference: Burman C-F, Sonesson C, Guilbaud O. A recycling framework for the construction of Bonferroni-based multiple tests. Statistics in Medicine 2009; 28(5):739-761.
– reference: EMA. Reflection Paper on Methodological Issues in Confirmatory Clinical Trials Planned with an Adaptive Design. European Medicines Agency: London, UK, 2007. http://www.ema.europa.eu.
– reference: Posch M, Bauer P, Brannath W. Issues in designing flexible trials. Statistics in Medicine 2003; 22(6):953-969.
– reference: Wang S-J, Hung HM, O'Neil RT. Impacts on type I error rate with inappropriate use of learn and confirm in confirmatory adaptive design trials. Biometrical Journal 2010; 52(6):798-810.
– reference: Maca J, Bhattacharya S, Dragalin V, Gallo P, Krams M. Adaptive seamless phase II/III designs - background, operational aspects, and examples. Drug Information Journal 2006; 40:463-473.
– reference: Victor A, Hommel G. Combining adaptive designs with control of the false discovery rate-a generalized definition for a global p-value. Biometrical Journal 2007; 49(1):94-106.
– reference: Chuang-Stein C, Bretz F, Komiyama O, Quinlan J. Interactions with regulatory agencies to enhance the understanding and acceptance of adaptive designs. Regulatory Affairs Focus 2009; 14(4):36-42.
– reference: Burman C-F, Sonesson C. Are flexible designs sound? Biometrics 2006; 62(3):664-669.
– reference: Graf AC, Bauer P, Glimm E, Koenig F. Maximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications. Biometrical Journal 2014; 56(4):614-630.
– reference: Bowden J, Glimm E. Unbiased estimation of selected treatment means in two-stage trials. Biometrical Journal 2008; 50(4):515-527.
– reference: Wang S-J, Hung HMJ, O'Neill RT. Adaptive patient enrichment designs in therapeutic trials. Biometrical Journal 2009; 51(2):358-374.
– reference: Bauer P. Sequential tests of hypotheses in consecutive trials. Biometrical Journal 1989; 31:663-676.
– reference: Jennison C, Turnbull BW. Adaptive seamless designs: selection and prospective testing of hypotheses. Journal of Biopharmaceutical Statistics 2007; 17(6):1135-1161.
– reference: O'Neill RT. Secondary endpoints cannot be validly analyzed if the primary endpoint does not demonstrate clear statistical significance. Controlled Clinical Trials 1997; 18:550-556.
– reference: Gould AL. Interim analysis for monitoring clinical trials that do not materially affect the type I error rate. Statistics in Medicine 1992; 11:53-66.
– reference: Brannath W, Zuber E, Branson M, Bretz F, Gallo P, Posch M, Racine-Poon A. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy on oncology. Statistics in Medicine 2009; 28:1445-1463.
– reference: Lehmacher W, Kieser M, Hothorn L. Sequential and multiple testing for dose-response analysis. Drug Information Journal 2000; 34:591-597.
– reference: Chen JJ, Lu T-P, Chen D-T, Wang S-J. Biomarker adaptive designs in clinical trials. Translational Cancer Research 2014; 3(3):279-292.
– reference: Denne JS. Sample size recalculation using conditional power. Statistics in Medicine 2001; 20:2645-2660.
– reference: König F, Brannath W, Bretz F, Posch M. Adaptive Dunnett tests for treatment selection. Statistics in Medicine 2008; 27:1612-1625.
– reference: Timmesfeld N, Schäfer H, Müller H-H. Increasing the sample size during clinical trials with t-distributed test statistics without inflating the type I error rate. Statistics in Medicine 2007; 26(12):2449-2464.
– reference: Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. Statistics in Medicine 2009; 28(4):586-604.
– reference: Wang S-J, O'Neill RT, Hung HM. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics 2007; 6(3):227-244.
– reference: Glimm E. Comments on Adaptive increase in sample size when interim results are promising: A practical guide with examples by CR Mehta and SJ Pocock. Statistics in Medicine 2012; 31(1):98-99.
– reference: Friede T, Parsons N, Stallard N. A conditional error function approach for subgroup selection in adaptive clinical trials. Statistics in Medicine 2012; 31(30):4309-4320.
– reference: Posch M, König F, Branson M, Brannath W, Dunger-Baldauf C, Bauer P. Testing and estimating in flexible group sequential designs with adaptive treatment selection. Statistics in Medicine 2005; 2443:3697-3714.
– reference: Wang S-J, Hung HM. Adaptive enrichment with subpopulation selection at interim: Methodologies, applications and design considerations. Contemporary Clinical Trials 2013; 36(2):673-681.
– reference: Brannath W, Gutjahr G, Bauer P. Probabilistic foundation of confirmatory adaptive designs. Journal of the American Statistical Association 2012; 107:824-832.
– reference: Klinglmueller F, Posch M, Koenig F. Adaptive graph-based multiple testing procedures. Pharmaceutical Statistics 2014; 13(6):345-356.
– reference: Bauer P, Brannath W. The advantages and disadvantages of adaptive designs for clinical trials. Drug Discovery Today 2004; 9:351-357.
– reference: Graf A, Posch M, Koenig F. Adaptive designs for subpopulation analysis optimizing utility functions. Biometrical Journal 2015; 57(1):76-89.
– reference: Case LD, Morgan TM, Davis CE. Optimal restricted two-stage designs. Controlled Clinical Trials 1987; 8:146-156.
– reference: Wassmer G. Multistage adaptive test procedures based on Fisher's product criterion. Biometrical Journal 1999; 41:279-293.
– reference: Quinlan JA, Krams M. Implementing adaptive designs: logistical and operational considerations. Drug Information Journal 2006; 40:437-444.
– reference: Stallard N, Todd S. Sequential designs for phase III clinical trials incorporating treatment selection. Statistics in Medicine 2003; 22(5):689-703.
– reference: Antonijevic Z, Gallo G, Chuang-Stein C, Dragalin V, Loewy J, Menon S, Miller ER, CC Morgan, Sanchez M. Views on emerging issues pertaining to data monitoring committees for adaptive trials. Therapeutic Innovation & Regulatory Science 2013; 47:495-502.
– reference: Schmidli H, Bretz F, Racine-Poon A. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint. Statistics in Medicine 2007; 26(27):4925-4938.
– reference: Zeymer U, Suryapranata H, Monassier JP, Opolski G, Davies J, Rasmanis G, Linssen G, U Tebbe, Schröder R, Tiemann R, Machnig T, Neuhaus KL. The Na+/H+ exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (escami) trial. Journal of the American College of Cardiology 2001; 38(6):E1644-E1650.
– reference: Friede T, Kieser M. Sample size recalculation in internal pilot study designs: a review. Biometrical Journal 2006; 48(4):537-555.
– reference: Mehta CR, Tsiatis AA. Flexible sample size considerations using information-based interim monitoring. Drug Information Journal 2001; 35:1095-1112.
– reference: Friede T, Parsons N, Stallard N, Todd S, Valdes Marquez E, Chataway J, Nicholas R. Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: An application in multiple sclerosis. Statistics in Medicine 2011; 30(13):1528-1540.
– reference: Cui L, Hung HMJ, Wang S-J. Modification of sample size in group sequential clinical trials. Biometrics 1999; 55:853-857.
– reference: Brannath W, Bauer P, Posch M. On the efficiency of adaptive designs for flexible interim decisions in clinical trials. Journal of Statistical Planning and Inference 2006; 136(6):1956-1961.
– reference: Posch M, Bauer P. Adaptive two stage designs and the conditional error function. Biometrical Journal 1999; 41:689-696.
– reference: O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics 1984; 40:1079-1087.
– reference: Tamhane AC, Wu Y, Mehta CR. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (ii): sample size re-estimation. Statistics in Medicine 2012; 31(19):2041-2054.
– reference: Desseaux K, Porcher R. Flexible two-stage design with sample size reassessment for survival trials. Statistics in Medicine 2007; 26(27):5002-5013.
– reference: Jennison C, Turnbull BW. Efficient group sequential designs when there are several effect sizes under consideration. Statistics in Medicine 2006; 25(6):917-932.
– reference: Barnes PJ, Pocock SJ, Magnussen H. Integrating indacaterol dose selection in a clinical study in copd using an adaptive seamless design. Pulmonary Pharmacology & Therapeutics 2010; 23:165-171.
– reference: Wittes J, Brittain E. The role of internal pilot studies in increasing the efficiency of clinical trials. Statistics in Medicine 1990; 9:65-72.
– reference: Kieser M, Bauer P, Lehmacher W. Inference on multiple endpoints in clinical trials with adaptive interim analyses. Biometrical Journal 1999; 41:261-277.
– reference: Gao P, Liu L, Mehta C. Adaptive sequential testing for multiple comparisons. Journal of Biopharmaceutical Statistics 2014; 24(5):1035-1058.
– reference: Heritier S, Lô SN, Morgan CC. An adaptive confirmatory trial with treatment selection: practical experiences and unbalanced randomization. Statistics in Medicine 2011; 30:1541-1554.
– reference: Hung HMJ, Wang S-J, Yang P. Some challenges with statistical inference in adaptive designs. Journal of Biopharmaceutical Statistics 2014; 24(5):1059-1072.
– reference: Friede T, Kieser M. A comparison of methods for adaptive sample size adjustment. Statistics in Medicine 2001; 20(24):3861-3873.
– reference: Brannath W, Koenig F, Bauer P. Multiplicity and flexibility in clinical trials. Pharmaceutical Statistics 2007; 6(3):205-216.
– reference: Hu F, Rosenberger WF. The Theory of Response-Adaptive Randomization in Clinical trials. John Wiley & Sons: Hoboken, 2006.
– reference: Magirr D, Jaki T, Posch M, Klinglmüller F. Simultaneous confidence intervals that are compatible with closed testing in adaptive designs. Biometrika 2013; 100(4):985-996.
– reference: Posch M, Proschan MA. Unplanned adaptations before breaking the blind. Statistics in Medicine 2012; 31(30):4146-4153.
– reference: Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J. Adaptive designs in clinical drug development - an executive summary of the PhRMA working group. Journal of Biopharmaceutical Statistics 2006; 16:275-283.
– reference: Brannath W, Posch M, Bauer P. Recursive combination tests. Journal of the American Statistical Association 2002; 97:236-244.
– reference: Birkett MA, Day SJ. Internal pilot studies for estimating sample size. Statistics in Medicine 1994; 13:2455-2463.
– reference: Jahn-Eimermacher A, Ingel K. Adaptive trial design: A general methodology for censored time to event data. Contemporary Clinical Trials 2009; 30(2):171-177.
– reference: Jennison C, Turnbull BW. Mid-course sample size modification in clinical trial. Statistics in Medicine 2003; 22:971-993.
– reference: Liu Q, Proschan MA, Pledger GW. A unified theory of two-stage adaptive designs. Journal of the American Statistical Association 2002; 97:1034-1041.
– reference: Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Chapman & Hall/CRC: Boca Raton, London, New York, Washington, D.C., 2000.
– reference: Müller H-H, Schäfer H. Adaptive group sequential designs for clinical trials: Combining the advantages of adaptive and of classical group sequential approaches. Biometrics 2001; 57:886-891.
– reference: Brannath W, König F, Bauer P. Estimation in flexible two stage designs. Statistics in Medicine 2006; 25(19):3366-3381.
– reference: Gould AL. Planning and revising the sample size for a trial. Statistics in Medicine 1995; 14:1039-1051.
– reference: Schneider S, Schmidli H, Friede T. Blinded sample size re-estimation for recurrent event data with time trends. Statistics in Medicine 2013; 32(30):5448-5457.
– reference: Gao P, Liu L, Mehta C. Exact inference for adaptive group sequential designs. Statistics in Medicine 2013; 32(23):3991-4005.
– reference: Chen YH, DeMets DL, Lan KKG. Increasing the sample size when the unblinded interim result is promising. Statistics in Medicine 2004; 23(7):1023-1038.
– reference: Mehta C, Gao P. Population enrichment designs: case study of a large multinational trial. Journal of Biopharmaceutical Statistics 2011; 21(4):831-845.
– reference: Bretz F, Posch M, Glimm E, Klinglmüller F, Maurer W, Rohmeyer K. Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests. Biometrical Journal 2011; 53(6):894-913.
– reference: Wassmer G. On sample size determination in multi-armed confirmatory adaptive designs. Journal of Biopharmaceutical Statistics 2011; 21:802-817.
– reference: Müller HH, Schäfer H. A general statistical principle for changing a design any time during the course of a trial. Statistics in Medicine 2004; 23:2497-2508.
– reference: Gaydos B, Anderson KM, Berry D, Burnham N, Chuang-Stein C, Dudinak J, Fardipour P, P Gallo, Givens S, Lewis R, Maca J, Pinheiro J, Pritchett Y, Krams M. Good practices for adaptive clinical trials in pharmaceutical product development. Drug Information Journal 2009; 43:539-565.
– reference: Dragalin V. Adaptive designs: Terminology and classification. Drug Information Journal 2006; 40:425-435.
– reference: Mehta CR, Pocock SJ. Adaptive increase in sample size when interim results are promising: A practical guide with examples. Statistics in Medicine 2011; 30(28):3267-3284.
– reference: Lehmacher W, Wassmer G, Reitmeir P. Procedures for two-sample comparisons with multiple endpoints controlling the experimentwise error rate. Biometrics 1991; 47(2):511-521.
– reference: Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, RJ Phillips, Caceres H, Lopez Gutierrez JC, Ballona R, Friedlander SF, Powell J, Perek D, Metz B, Barbarot S, Maruani A, Szalai ZZ, Krol A, Boccara O, Foelster-Holst R, Febrer Bosch MI, Su J, Buckova H, Torrelo A, Cambazard F, Grantzow R, Wargon O, Wyrzykowski D, Roessler J, J Bernabeu-Wittel, Valencia AM, Przewratil P, Glick S, Pope E, Birchall N, Benjamin L, Mancini AJ, Vabres P, Souteyrand P, Frieden IJ, Berul CI, Mehta CR, Prey S, Boralevi F, Morgan CC, S Heritier, Delarue A, Voisard JJ. A randomized controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine 2015; 72(8):735-746.
– reference: Proschan MA, Hunsberger SA. Designed extension of studies based on conditional power. Biometrics 1995; 51:1315-1324.
– reference: Magirr D, Stallard N, Jaki T. Flexible sequential designs for multi-arm clinical trials. Statistics in Medicine 2014; 33:3269-3279.
– reference: EMA. Guideline on Clinical Trials in Small Populations (chmp/ewp/83561/2005). European Medicines Agency: London, UK, 2006. http://www.ema.europa.eu.
– reference: Bretz F, Branson M, Burman CF, Chuang-Stein C, Coffey CS. Adaptivity in drug discovery and development. Drug Development Research 2009; 70:169-190.
– reference: Wassmer G, Vandemeulebroecke M. A brief review on software developments for group sequential and adaptive designs. Biometrical Journal 2006; 48(4):732-737.
– reference: Chang M. Adaptive Design Theory and Implementation Using SAS and R. Chapman and Hall/CRC: Boca Raton, London, New York, 2008.
– reference: Stallard N, Friede T. A group-sequential design for clinical trials with treatment selection. Statistics in Medicine 2008; 27:6209-6227.
– reference: Lawrence J, Hung HM. Estimation and confidence intervals after adjusting the maximum information. Biometrical Journal 2003; 45(2):143-152.
– reference: Marcus R, Peritz E, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976; 63:655-660.
– reference: Carreras M, Gutjahr G, Brannath W. Adaptive seamless designs with interim treatment selection: a case study in oncology. Statistics in Medicine 2015; Early View.
– reference: Mehta C, Schäfer H, Daniel H, Irle S. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints. Statistics in Medicine 2014; 33(26):4515-4531.
– reference: Jenkins M, Stone A, Jennison C. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharmaceutical Statistics 2011; 10:347-356.
– reference: Bauer P, König F. The risks of methodology aversion in drug regulation. Nature Reviews Drug Discovery 2014; 13(5):317-318.
– reference: Sugitani T, Bretz F, Maurer W. A simple and flexible graphical approach for adaptive group-sequential clinical trials. Journal of Biopharmaceutical Statistics 2014; Accepted.
– reference: Gould AL, Shih WJ. Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance. Communications in Statistics - Theory and Methods 1992; 21:2833-2853.
– reference: Bauer P, Posch M. Letter to the Editor: Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections. Statistics in Medicine 2004; 23:1333-1335.
– reference: Bauer P. Multistage testing with adaptive designs. Biometrie und Informatik in Medizin und Biologie 1989; 20:130-148.
– reference: Hung HMJ, Wang S-J, O'Neill R. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials. Journal of Biopharmaceutical Statistics 2007; 17(6):1201-1210.
– reference: Sugitani T, Hamasaki T, Hamada C. Partition testing in confirmatory adaptive designs with structured objectives. Biometrical Journal 2013; 55(3):341-359.
– reference: Wassmer G. A comparison of two methods for adaptive interim analyses in clinical trials. Biometrics 1998; 54:696-705.
– reference: Posch M, Maurer W, Bretz F. Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim. Pharmaceutical Statistics 2011; 10(2):96-104.
– reference: Emerson SS. Statistical packages for group sequential methods. The American Statistician 1996; 50:183-192.
– reference: Bauer P, Kieser M. Combining different phases in the development of medical treatments within a single trial. Statistics in Medicine 1999; 18:1833-1848.
– reference: Phillips AJ, Keene ON. Adaptive designs for pivotal trials: discussion points from the PSI adaptive design expert group. Pharmaceutical Statistics 2006; 5(1):61-66.
– reference: Mehta C, Gao P, Bhatt DL, Harrington RA, Skerjanec S, Ware JH. Optimizing trial design sequential, adaptive, and enrichment strategies. Circulation 2009; 119(4):597-605.
– reference: Wang S-J, Brannath W, Brückner M, James Hung HM, Koch A. Unblinded adaptive statistical information design based on clinical endpoint or biomarker. Statistics in Biopharmaceutical Research 2013; 5(4):293-310.
– reference: Elsäßer A, Regnstrom J, Vetter T, Koenig F, Hemmings RJ, Greco M, Papaluca-Amati M, Posch M. Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency. Trials 2014; 15(1):383.
– reference: Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics 1999; 55(4):1286-1290.
– reference: Magirr D, Jaki T, Koenig F, Posch M. Adaptive survival trials. arXiv preprint arXiv:1405.1569 2014.
– reference: Bauer P, Koenig F, Brannath W, Posch M. Selection and bias - two hostile brothers. Statistics in Medicine 2010; 29(1):1-13.
– reference: Coburger S, Wassmer G. Sample size reassessment in adaptive clinical trials using a bias corrected estimate. Biometrical Journal 2003; 45(7):812-825.
– reference: Bretz F, König F, Brannath W, Glimm E, Posch M. Tutorial in biostatistics: Adaptive designs for confirmatory clinical trials. Statistics in Medicine 2009; 28:1181-1217.
– reference: Irle S, Schäfer H. Interim design modificcations in time-to-event studies. Journal of the American Statistical Association 2014; 107:341-348.
– reference: Hommel G. Adaptive modifications of hypotheses after an interim analysis. Biometrical Journal 2001; 43:581-589.
– reference: Tsiatis AA, Mehta C. On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika 2003; 90:367-378.
– reference: Shun Z, Yuan W, Brady WE, Hsu H. Type I error in sample size re-estimations based on observed treatment difference. Statistics in Medicine 2001; 20(4):497-513.
– reference: Friede Tim, Stallard Nigel. A comparison of methods for adaptive treatment selection. Biometrical Journal 2008; 50(5):767-781.
– reference: Gugerli US, Maurer W, Mellein B. Internally adaptive designs for parallel group trials. Drug Information Journal 1993; 27:721-732.
– reference: Zhou J, Adewale A, Shentu Y, Liu J, Anderson K. Information-based sample size re-estimation in group sequential design for longitudinal trials. Statistics in Medicine 2014; 33(22):3801-3814.
– reference: Bowden J, Glimm E. Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop-the-losers trials. Biometrical Journal 2014; 56(2):332-349.
– reference: Brannath W, Bauer P. Optimal conditional error functions for the control of conditional power. Biometrics 2004; 60:715-723.
– reference: Morgan C, Huyck S, Jenkins M, Chen L, Bedding A, Coffey C, Gaydos B, Wathen J. Adaptive design: Results of 2012 survey on perception and use. Therapeutic Innovation & Regulatory Science 2014; 48:473-481.
– reference: Bauer J, Einfalt P. Application of adaptive designs - a review. Biometrical Journal 2006; 8:1-16.
– reference: Posch M, Timmesfeld N, König F, Müller H-H. Conditional rejection probabilities of Student's t-test and design adaptation. Biometrical Journal 2004; 46:389-403.
– reference: Wassmer G, Reitmeir P, Kieser M, Lehmacher W. Procedures for testing multiple endpoints in clinical trials: An overview. Journal of Statistical Planning and Inference 1999; 82:69-81.
– reference: Schäfer H, Müller H-H. Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections. Statistics in Medicine 2001; 20:3741-3751.
– reference: Burman C-F, Lisovskaja V. The dual test: Safeguarding p-value combination tests for adaptive designs. Statistics in Medicine 2010; 29(7-8):797-807.
– reference: Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. Academic Press: New York, 1985.
– reference: Brannath W, Mehta CR, Posch M. Exact confidence bounds following adaptive group sequential tests. Biometrics 2009; 65(2):539-546.
– reference: Mehta CR, Bauer P, Posch M, Brannath W. Repeated confidence intervals for adaptive group sequential trials. Statistics in Medicine 2007; 26(30):5422-5433.
– reference: Schmidli H, Bretz F, Racine A, Maurer W. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations. Biometrical Journal 2006; 48(4):635-643.
– reference: Zhu L, Ni L, Yao B. Group sequential methods and software applications. The American Statistician 2011; 65:127-135.
– reference: Berry SM, Carlin BP, Lee JJ, Muller P. Bayesian Adaptive Methods for Clinical Trials. CRC Press: Boca Raton, 2010.
– reference: Scherag A, Hebebrand J, Schäfer H, Müller H-H. Flexible designs for genomewide association studies. Biometrics 2009; 65(3):815-821.
– reference: Proschan M, Lan G, Wittes J. Statistical Monitoring of Clinical Trials. A Unified Approach. Springer: Science & Business Media, 2006.
– reference: Donohue JF, Fogarty C, Lötvall J. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. American Journal of Respiratory and Critical Care Medicine 2010; 182:155-162.
– reference: Liu Q, Pledger GW. On design and inference for two-stage adaptive clinical trials with dependent data. Journal of Statistical Planning and Inference 2006; 136:1962-1984.
– reference: Faldum A, Hommel G. Strategies for including patients recruited during interim analysis of clinical trials. Journal of Biopharmaceutical Statistics 2007; 17(6):1211-1225.
– reference: Stallard N. A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information. Statistics in Medicine 2010; 29(9):959-971.
– reference: Hünseler C, Balling G, Röhlig C, Blickheuser R, Trieschmann U, Lieser U, Dohna-Schwake C, Gebauer C, Möller O, Hering F, Hoehn T., Schubert S, Hentschel R, Huth RG, Müller A, Müller C, Wassmer G, Hahn M, Harnischmacher U, Behr J, Roth B. Continuous infusion of clonidine in ventilated newborns and infants: A randomized controlled trial. Pediatric Critical Care Medicine 2014; 15:511-522.
– reference: Eichler H-G, Bloechl-Daum B, Abadie E, Barnett D, König F, Pearson S. Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. Nature Reviews Drug Discovery 2010; 9(4):277-291.
– reference: Stallard N, Hamborg T, Parsons N, Friede T. Adaptive designs for confirmatory clinical trials with subgroup selection. Journal of Biopharmaceutical Statistics 2014; 24(1):168-187.
– reference: Wassmer G. Planning and analyzing adaptive group sequential survival trials. Biometrical Journal 2006; 48(4):714-729.
– reference: Fisher LD. Self-designing clinical trials. Statistics in Medicine 1998; 17:1551-1562.
– reference: Wassmer G. Statistische Testverfahren für gruppensequentielle und adaptive Pläne in klinischen Studien. Theoretische Konzepte und deren praktische Umsetzung mit SAS. Verlag Alexander Mönch: Köln, 1999.
– reference: Coburger S, Wassmer G. Conditional point estimation in adaptive group sequential test designs. Biometrical Journal 2001; 43(7):821-833.
– reference: FDA. Draft Guidance for Industry Adaptive Design Clinical Trials for Drugs and Biologics. Food and Drug Administration. Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER): Rockville MD, USA, 2010. url=http://http://www.fda.gov/.
– volume: 43
  start-page: 581
  year: 2001
  end-page: 589
  article-title: Adaptive modifications of hypotheses after an interim analysis
  publication-title: Biometrical Journal
– volume: 33
  start-page: 4515
  issue: 26
  year: 2014
  end-page: 4531
  article-title: Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints
  publication-title: Statistics in Medicine
– volume: 29
  start-page: 959
  issue: 9
  year: 2010
  end-page: 971
  article-title: A confirmatory seamless phase II/III clinical trial design incorporating short‐term endpoint information
  publication-title: Statistics in Medicine
– volume: 62
  start-page: 664
  issue: 3
  year: 2006
  end-page: 669
  article-title: Are flexible designs sound?
  publication-title: Biometrics
– volume: 27
  start-page: 1612
  year: 2008
  end-page: 1625
  article-title: Adaptive Dunnett tests for treatment selection
  publication-title: Statistics in Medicine
– volume: 28
  start-page: 1445
  year: 2009
  end-page: 1463
  article-title: Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy on oncology
  publication-title: Statistics in Medicine
– volume: 23
  start-page: 1023
  issue: 7
  year: 2004
  end-page: 1038
  article-title: Increasing the sample size when the unblinded interim result is promising
  publication-title: Statistics in Medicine
– volume: 31
  start-page: 4146
  issue: 30
  year: 2012
  end-page: 4153
  article-title: Unplanned adaptations before breaking the blind
  publication-title: Statistics in Medicine
– volume: 27
  start-page: 6209
  year: 2008
  end-page: 6227
  article-title: A group‐sequential design for clinical trials with treatment selection
  publication-title: Statistics in Medicine
– volume: 40
  start-page: 425
  year: 2006
  end-page: 435
  article-title: Adaptive designs: Terminology and classification
  publication-title: Drug Information Journal
– volume: 33
  start-page: 4734
  issue: 27
  year: 2014
  end-page: 4742
  article-title: Connections between permutation and t‐tests: relevance to adaptive methods
  publication-title: Statistics in Medicine
– volume: 54
  start-page: 696
  year: 1998
  end-page: 705
  article-title: A comparison of two methods for adaptive interim analyses in clinical trials
  publication-title: Biometrics
– volume: 25
  start-page: 23
  year: 2006
  end-page: 36
  article-title: The reassessment of trial perspectives from interim data – a critical view
  publication-title: Statistics In Medicine
– volume: 45
  start-page: 143
  issue: 2
  year: 2003
  end-page: 152
  article-title: Estimation and confidence intervals after adjusting the maximum information
  publication-title: Biometrical Journal
– volume: 10
  start-page: 347
  year: 2011
  end-page: 356
  article-title: An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints
  publication-title: Pharmaceutical Statistics
– volume: 25
  start-page: 3366
  issue: 19
  year: 2006
  end-page: 3381
  article-title: Estimation in flexible two stage designs
  publication-title: Statistics in Medicine
– volume: 136
  start-page: 1962
  year: 2006
  end-page: 1984
  article-title: On design and inference for two‐stage adaptive clinical trials with dependent data
  publication-title: Journal of Statistical Planning and Inference
– volume: 17
  start-page: 1201
  issue: 6
  year: 2007
  end-page: 1210
  article-title: Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials
  publication-title: Journal of Biopharmaceutical Statistics
– volume: 6
  start-page: 205
  issue: 3
  year: 2007
  end-page: 216
  article-title: Multiplicity and flexibility in clinical trials
  publication-title: Pharmaceutical Statistics
– volume: 57
  start-page: 76
  issue: 1
  year: 2015
  end-page: 89
  article-title: Adaptive designs for subpopulation analysis optimizing utility functions
  publication-title: Biometrical Journal
– volume: 20
  start-page: 130
  year: 1989
  end-page: 148
  article-title: Multistage testing with adaptive designs
  publication-title: Biometrie und Informatik in Medizin und Biologie
– year: 2014
– year: 1998
– volume: 13
  start-page: 2455
  year: 1994
  end-page: 2463
  article-title: Internal pilot studies for estimating sample size
  publication-title: Statistics in Medicine
– volume: 41
  start-page: 279
  year: 1999
  end-page: 293
  article-title: Multistage adaptive test procedures based on Fisher's product criterion
  publication-title: Biometrical Journal
– volume: 30
  start-page: 3267
  issue: 28
  year: 2011
  end-page: 3284
  article-title: Adaptive increase in sample size when interim results are promising: A practical guide with examples
  publication-title: Statistics in Medicine
– volume: 41
  start-page: 261
  year: 1999
  end-page: 277
  article-title: Inference on multiple endpoints in clinical trials with adaptive interim analyses
  publication-title: Biometrical Journal
– volume: 28
  start-page: 1181
  year: 2009
  end-page: 1217
  article-title: Tutorial in biostatistics: Adaptive designs for confirmatory clinical trials
  publication-title: Statistics in Medicine
– volume: 40
  start-page: 1079
  year: 1984
  end-page: 1087
  article-title: Procedures for comparing samples with multiple endpoints
  publication-title: Biometrics
– volume: 6
  start-page: 227
  issue: 3
  year: 2007
  end-page: 244
  article-title: Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset
  publication-title: Pharmaceutical Statistics
– volume: 34
  start-page: 591
  year: 2000
  end-page: 597
  article-title: Sequential and multiple testing for dose‐response analysis
  publication-title: Drug Information Journal
– year: 2008
– volume: 23
  start-page: 1519
  issue: 12
  year: 2007
  end-page: 1526
  article-title: Two‐stage designs applying methods differing in costs
  publication-title: Bioinformatics
– volume: 119
  start-page: 597
  issue: 4
  year: 2009
  end-page: 605
  article-title: Optimizing trial design sequential, adaptive, and enrichment strategies
  publication-title: Circulation
– volume: 70
  start-page: 169
  year: 2009
  end-page: 190
  article-title: Adaptivity in drug discovery and development
  publication-title: Drug Development Research
– volume: 51
  start-page: 358
  issue: 2
  year: 2009
  end-page: 374
  article-title: Adaptive patient enrichment designs in therapeutic trials
  publication-title: Biometrical Journal
– volume: 65
  start-page: 815
  issue: 3
  year: 2009
  end-page: 821
  article-title: Flexible designs for genomewide association studies
  publication-title: Biometrics
– volume: 50
  start-page: 1029
  year: 1994
  end-page: 1041
  article-title: Evaluation of experiments with adaptive interim analyses
  publication-title: Biometrics
– volume: 13
  start-page: 345
  issue: 6
  year: 2014
  end-page: 356
  article-title: Adaptive graph‐based multiple testing procedures
  publication-title: Pharmaceutical Statistics
– volume: 60
  start-page: 715
  year: 2004
  end-page: 723
  article-title: Optimal conditional error functions for the control of conditional power
  publication-title: Biometrics
– volume: 52
  start-page: 798
  issue: 6
  year: 2010
  end-page: 810
  article-title: Impacts on type I error rate with inappropriate use of learn and confirm in confirmatory adaptive design trials
  publication-title: Biometrical Journal
– volume: 14
  start-page: 1039
  year: 1995
  end-page: 1051
  article-title: Planning and revising the sample size for a trial
  publication-title: Statistics in Medicine
– volume: 5
  start-page: 293
  issue: 4
  year: 2013
  end-page: 310
  article-title: Unblinded adaptive statistical information design based on clinical endpoint or biomarker
  publication-title: Statistics in Biopharmaceutical Research
– volume: 29
  start-page: 797
  issue: 7‐8
  year: 2010
  end-page: 807
  article-title: The dual test: Safeguarding p‐value combination tests for adaptive designs
  publication-title: Statistics in Medicine
– volume: 18
  start-page: 1833
  year: 1999
  end-page: 1848
  article-title: Combining different phases in the development of medical treatments within a single trial
  publication-title: Statistics in Medicine
– volume: 90
  start-page: 367
  year: 2003
  end-page: 378
  article-title: On the inefficiency of the adaptive design for monitoring clinical trials
  publication-title: Biometrika
– volume: 19
  start-page: 901
  year: 2000
  end-page: 911
  article-title: Re‐calculating the sample size in internal pilot study designs with control of the type I error rate
  publication-title: Statistics in Medicine
– volume: 26
  start-page: 2449
  issue: 12
  year: 2007
  end-page: 2464
  article-title: Increasing the sample size during clinical trials with t‐distributed test statistics without inflating the type I error rate
  publication-title: Statistics in Medicine
– volume: 45
  start-page: 812
  issue: 7
  year: 2003
  end-page: 825
  article-title: Sample size reassessment in adaptive clinical trials using a bias corrected estimate
  publication-title: Biometrical Journal
– volume: 27
  start-page: 721
  year: 1993
  end-page: 732
  article-title: Internally adaptive designs for parallel group trials
  publication-title: Drug Information Journal
– volume: 51
  start-page: 1315
  year: 1995
  end-page: 1324
  article-title: Designed extension of studies based on conditional power
  publication-title: Biometrics
– volume: 30
  start-page: 1528
  issue: 13
  year: 2011
  end-page: 1540
  article-title: Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: An application in multiple sclerosis
  publication-title: Statistics in Medicine
– volume: 48
  start-page: 732
  issue: 4
  year: 2006
  end-page: 737
  article-title: A brief review on software developments for group sequential and adaptive designs
  publication-title: Biometrical Journal
– year: 2007
– volume: 26
  start-page: 5002
  issue: 27
  year: 2007
  end-page: 5013
  article-title: Flexible two‐stage design with sample size reassessment for survival trials
  publication-title: Statistics in Medicine
– volume: 9
  start-page: 277
  issue: 4
  year: 2010
  end-page: 291
  article-title: Relative efficacy of drugs: an emerging issue between regulatory agencies and third‐party payers
  publication-title: Nature Reviews Drug Discovery
– year: 2014
  article-title: Adaptive survival trials
  publication-title: arXiv preprint arXiv:1405.1569
– volume: 48
  start-page: 473
  year: 2014
  end-page: 481
  article-title: Adaptive design: Results of 2012 survey on perception and use
  publication-title: Therapeutic Innovation & Regulatory Science
– volume: 11
  start-page: 53
  year: 1992
  end-page: 66
  article-title: Interim analysis for monitoring clinical trials that do not materially affect the type I error rate
  publication-title: Statistics in Medicine
– volume: 31
  start-page: 663
  year: 1989
  end-page: 676
  article-title: Sequential tests of hypotheses in consecutive trials
  publication-title: Biometrical Journal
– volume: 107
  start-page: 341
  year: 2014
  end-page: 348
  article-title: Interim design modificcations in time‐to‐event studies
  publication-title: Journal of the American Statistical Association
– start-page: 139
  year: 2014
  end-page: 155
– volume: 40
  start-page: 437
  year: 2006
  end-page: 444
  article-title: Implementing adaptive designs: logistical and operational considerations
  publication-title: Drug Information Journal
– volume: 26
  start-page: 5422
  issue: 30
  year: 2007
  end-page: 5433
  article-title: Repeated confidence intervals for adaptive group sequential trials
  publication-title: Statistics in Medicine
– volume: 136
  start-page: 1956
  issue: 6
  year: 2006
  end-page: 1961
  article-title: On the efficiency of adaptive designs for flexible interim decisions in clinical trials
  publication-title: Journal of Statistical Planning and Inference
– volume: 48
  start-page: 537
  issue: 4
  year: 2006
  end-page: 555
  article-title: Sample size recalculation in internal pilot study designs: a review
  publication-title: Biometrical Journal
– year: 2010
– volume: 32
  start-page: 5448
  issue: 30
  year: 2013
  end-page: 5457
  article-title: Blinded sample size re‐estimation for recurrent event data with time trends
  publication-title: Statistics in Medicine
– volume: 8
  start-page: 146
  year: 1987
  end-page: 156
  article-title: Optimal restricted two‐stage designs
  publication-title: Controlled Clinical Trials
– volume: 17
  start-page: 1135
  issue: 6
  year: 2007
  end-page: 1161
  article-title: Adaptive seamless designs: selection and prospective testing of hypotheses
  publication-title: Journal of Biopharmaceutical Statistics
– volume: 22
  start-page: 689
  issue: 5
  year: 2003
  end-page: 703
  article-title: Sequential designs for phase III clinical trials incorporating treatment selection
  publication-title: Statistics in Medicine
– volume: 55
  start-page: 1286
  issue: 4
  year: 1999
  end-page: 1290
  article-title: Adaptive sample size calculations in group sequential trials
  publication-title: Biometrics
– volume: 97
  start-page: 236
  year: 2002
  end-page: 244
  article-title: Recursive combination tests
  publication-title: Journal of the American Statistical Association
– volume: 24
  start-page: 168
  issue: 1
  year: 2014
  end-page: 187
  article-title: Adaptive designs for confirmatory clinical trials with subgroup selection
  publication-title: Journal of Biopharmaceutical Statistics
– volume: 93
  start-page: 1
  year: 2006
  end-page: 21
  article-title: Adaptive and nonadaptive group sequential tests
  publication-title: Biometrika
– volume: 31
  start-page: 2041
  issue: 19
  year: 2012
  end-page: 2054
  article-title: Adaptive extensions of a two‐stage group sequential procedure for testing primary and secondary endpoints (ii): sample size re‐estimation
  publication-title: Statistics in Medicine
– volume: 24
  start-page: 1035
  issue: 5
  year: 2014
  end-page: 1058
  article-title: Adaptive sequential testing for multiple comparisons
  publication-title: Journal of Biopharmaceutical Statistics
– volume: 40
  start-page: 421
  issue: 22
  year: 2006
  end-page: 484
  article-title: White papers
  publication-title: Drug Information Journal
– volume: 21
  start-page: 2833
  year: 1992
  end-page: 2853
  article-title: Sample size re‐estimation without unblinding for normally distributed outcomes with unknown variance
  publication-title: Communications in Statistics ‐ Theory and Methods
– volume: 20
  start-page: 497
  issue: 4
  year: 2001
  end-page: 513
  article-title: Type I error in sample size re‐estimations based on observed treatment difference
  publication-title: Statistics in Medicine
– volume: 17
  start-page: 1551
  year: 1998
  end-page: 1562
  article-title: Self‐designing clinical trials
  publication-title: Statistics in Medicine
– volume: 63
  start-page: 655
  year: 1976
  end-page: 660
  article-title: On closed testing procedures with special reference to ordered analysis of variance
  publication-title: Biometrika
– volume: 21
  start-page: 831
  issue: 4
  year: 2011
  end-page: 845
  article-title: Population enrichment designs: case study of a large multinational trial
  publication-title: Journal of Biopharmaceutical Statistics
– year: 2013
– year: 1985
– start-page: 77
  year: 2014
  end-page: 93
– volume: 33
  start-page: 3269
  year: 2014
  end-page: 3279
  article-title: Flexible sequential designs for multi‐arm clinical trials
  publication-title: Statistics in Medicine
– year: 2009
– volume: 47
  start-page: 511
  issue: 2
  year: 1991
  end-page: 521
  article-title: Procedures for two‐sample comparisons with multiple endpoints controlling the experimentwise error rate
  publication-title: Biometrics
– volume: 9
  start-page: 65
  year: 1990
  end-page: 72
  article-title: The role of internal pilot studies in increasing the efficiency of clinical trials
  publication-title: Statistics in Medicine
– volume: 31
  start-page: 4309
  issue: 30
  year: 2012
  end-page: 4320
  article-title: A conditional error function approach for subgroup selection in adaptive clinical trials
  publication-title: Statistics in Medicine
– volume: 8
  start-page: 1
  year: 2006
  end-page: 16
  article-title: Application of adaptive designs ‐ a review
  publication-title: Biometrical Journal
– volume: 23
  start-page: 2497
  year: 2004
  end-page: 2508
  article-title: A general statistical principle for changing a design any time during the course of a trial
  publication-title: Statistics in Medicine
– volume: 13
  start-page: 317
  issue: 5
  year: 2014
  end-page: 318
  article-title: The risks of methodology aversion in drug regulation
  publication-title: Nature Reviews Drug Discovery
– volume: 107
  start-page: 824
  year: 2012
  end-page: 832
  article-title: Probabilistic foundation of confirmatory adaptive designs
  publication-title: Journal of the American Statistical Association
– volume: 2443
  start-page: 3697
  year: 2005
  end-page: 3714
  article-title: Testing and estimating in flexible group sequential designs with adaptive treatment selection
  publication-title: Statistics in Medicine
– volume: Early View
  year: 2015
  article-title: Adaptive seamless designs with interim treatment selection: a case study in oncology
  publication-title: Statistics in Medicine
– volume: 65
  start-page: 539
  issue: 2
  year: 2009
  end-page: 546
  article-title: Exact confidence bounds following adaptive group sequential tests
  publication-title: Biometrics
– volume: 43
  start-page: 539
  year: 2009
  end-page: 565
  article-title: Good practices for adaptive clinical trials in pharmaceutical product development
  publication-title: Drug Information Journal
– volume: 25
  start-page: 917
  issue: 6
  year: 2006
  end-page: 932
  article-title: Efficient group sequential designs when there are several effect sizes under consideration
  publication-title: Statistics in Medicine
– volume: 56
  start-page: 614
  issue: 4
  year: 2014
  end-page: 630
  article-title: Maximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications
  publication-title: Biometrical Journal
– volume: 50
  start-page: 183
  year: 1996
  end-page: 192
  article-title: Statistical packages for group sequential methods
  publication-title: The American Statistician
– volume: 22
  start-page: 971
  year: 2003
  end-page: 993
  article-title: Mid‐course sample size modification in clinical trial
  publication-title: Statistics in Medicine
– volume: 29
  start-page: 1
  issue: 1
  year: 2010
  end-page: 13
  article-title: Selection and bias – two hostile brothers
  publication-title: Statistics in Medicine
– volume: 24
  start-page: 1059
  issue: 5
  year: 2014
  end-page: 1072
  article-title: Some challenges with statistical inference in adaptive designs
  publication-title: Journal of Biopharmaceutical Statistics
– volume: 30
  start-page: 1541
  year: 2011
  end-page: 1554
  article-title: An adaptive confirmatory trial with treatment selection: practical experiences and unbalanced randomization
  publication-title: Statistics in Medicine
– volume: 30
  start-page: 171
  issue: 2
  year: 2009
  end-page: 177
  article-title: Adaptive trial design: A general methodology for censored time to event data
  publication-title: Contemporary Clinical Trials
– volume: 21
  start-page: 802
  year: 2011
  end-page: 817
  article-title: On sample size determination in multi‐armed confirmatory adaptive designs
  publication-title: Journal of Biopharmaceutical Statistics
– volume: 48
  start-page: 714
  issue: 4
  year: 2006
  end-page: 729
  article-title: Planning and analyzing adaptive group sequential survival trials
  publication-title: Biometrical Journal
– volume: 60
  start-page: 910
  issue: 4
  year: 2004
  end-page: 918
  article-title: Estimation of a parameter and its exact confidence interval following sequential sample size reestimation trials
  publication-title: Biometrics
– volume: 100
  start-page: 985
  issue: 4
  year: 2013
  end-page: 996
  article-title: Simultaneous confidence intervals that are compatible with closed testing in adaptive designs
  publication-title: Biometrika
– volume: 5
  start-page: 61
  issue: 1
  year: 2006
  end-page: 66
  article-title: Adaptive designs for pivotal trials: discussion points from the PSI adaptive design expert group
  publication-title: Pharmaceutical Statistics
– volume: 50
  start-page: 515
  issue: 4
  year: 2008
  end-page: 527
  article-title: Unbiased estimation of selected treatment means in two‐stage trials
  publication-title: Biometrical Journal
– volume: 49
  start-page: 94
  issue: 1
  year: 2007
  end-page: 106
  article-title: Combining adaptive designs with control of the false discovery rate–a generalized definition for a global p‐value
  publication-title: Biometrical Journal
– volume: 48
  start-page: 635
  issue: 4
  year: 2006
  end-page: 643
  article-title: Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations
  publication-title: Biometrical Journal
– volume: 17
  start-page: 1211
  issue: 6
  year: 2007
  end-page: 1225
  article-title: Strategies for including patients recruited during interim analysis of clinical trials
  publication-title: Journal of Biopharmaceutical Statistics
– volume: 56
  start-page: 332
  issue: 2
  year: 2014
  end-page: 349
  article-title: Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop‐the‐losers trials
  publication-title: Biometrical Journal
– volume: 41
  start-page: 689
  year: 1999
  end-page: 696
  article-title: Adaptive two stage designs and the conditional error function
  publication-title: Biometrical Journal
– volume: 9
  start-page: 351
  year: 2004
  end-page: 357
  article-title: The advantages and disadvantages of adaptive designs for clinical trials
  publication-title: Drug Discovery Today
– year: 2015
– volume: 46
  start-page: 389
  year: 2004
  end-page: 403
  article-title: Conditional rejection probabilities of Student's t‐test and design adaptation
  publication-title: Biometrical Journal
– volume: 23
  start-page: 1333
  year: 2004
  end-page: 1335
  article-title: Letter to the Editor: Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections
  publication-title: Statistics in Medicine
– volume: 28
  start-page: 739
  issue: 5
  year: 2009
  end-page: 761
  article-title: A recycling framework for the construction of Bonferroni‐based multiple tests
  publication-title: Statistics in Medicine
– volume: 65
  start-page: 127
  year: 2011
  end-page: 135
  article-title: Group sequential methods and software applications
  publication-title: The American Statistician
– volume: 67
  start-page: 1039
  issue: 3
  year: 2011
  end-page: 1046
  article-title: An approach to the conditional error rate principle with nuisance parameters
  publication-title: Biometrics
– start-page: 259
  year: 2014
  end-page: 272
– volume: 72
  start-page: 735
  issue: 8
  year: 2015
  end-page: 746
  article-title: A randomized controlled trial of oral propranolol in infantile hemangioma
  publication-title: New England Journal of Medicine
– volume: 55
  start-page: 341
  issue: 3
  year: 2013
  end-page: 359
  article-title: Partition testing in confirmatory adaptive designs with structured objectives
  publication-title: Biometrical Journal
– volume: 35
  start-page: 1095
  year: 2001
  end-page: 1112
  article-title: Flexible sample size considerations using information‐based interim monitoring
  publication-title: Drug Information Journal
– volume: 20
  start-page: 3861
  issue: 24
  year: 2001
  end-page: 3873
  article-title: A comparison of methods for adaptive sample size adjustment
  publication-title: Statistics in Medicine
– volume: 38
  start-page: E1644
  issue: 6
  year: 2001
  end-page: E1650
  article-title: The Na+/H+ exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (escami) trial
  publication-title: Journal of the American College of Cardiology
– volume: 47
  start-page: 495
  year: 2013
  end-page: 502
  article-title: Views on emerging issues pertaining to data monitoring committees for adaptive trials
  publication-title: Therapeutic Innovation & Regulatory Science
– volume: 18
  start-page: 550
  year: 1997
  end-page: 556
  article-title: Secondary endpoints cannot be validly analyzed if the primary endpoint does not demonstrate clear statistical significance
  publication-title: Controlled Clinical Trials
– volume: 57
  start-page: 886
  year: 2001
  end-page: 891
  article-title: Adaptive group sequential designs for clinical trials: Combining the advantages of adaptive and of classical group sequential approaches
  publication-title: Biometrics
– volume: 97
  start-page: 1034
  year: 2002
  end-page: 1041
  article-title: A unified theory of two‐stage adaptive designs
  publication-title: Journal of the American Statistical Association
– year: 2000
– volume: 22
  start-page: 953
  issue: 6
  year: 2003
  end-page: 969
  article-title: Issues in designing flexible trials
  publication-title: Statistics in Medicine
– volume: 22
  start-page: 111
  year: 2001
  end-page: 116
  article-title: A self‐designing rule for clinical trials with arbitrary variables
  publication-title: Controlled Clinical Trials
– volume: 53
  start-page: 894
  issue: 6
  year: 2011
  end-page: 913
  article-title: Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests
  publication-title: Biometrical Journal
– volume: 10
  start-page: 96
  issue: 2
  year: 2011
  end-page: 104
  article-title: Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim
  publication-title: Pharmaceutical Statistics
– volume: 48
  start-page: 623
  issue: 4
  year: 2006
  end-page: 634
  article-title: Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: General concepts
  publication-title: Biometrical Journal
– volume: 31
  start-page: 98
  issue: 1
  year: 2012
  end-page: 99
  article-title: Comments on Adaptive increase in sample size when interim results are promising: A practical guide with examples by CR Mehta and SJ Pocock
  publication-title: Statistics in Medicine
– volume: 28
  start-page: 586
  issue: 4
  year: 2009
  end-page: 604
  article-title: A graphical approach to sequentially rejective multiple test procedures
  publication-title: Statistics in Medicine
– volume: 36
  start-page: 673
  issue: 2
  year: 2013
  end-page: 681
  article-title: Adaptive enrichment with subpopulation selection at interim: Methodologies, applications and design considerations
  publication-title: Contemporary Clinical Trials
– volume: 3
  start-page: 279
  issue: 3
  year: 2014
  end-page: 292
  article-title: Biomarker adaptive designs in clinical trials
  publication-title: Translational Cancer Research
– year: 2012
– volume: 25
  year: 2015
  article-title: Designing issues in confirmatory adaptive population enrichment trials
  publication-title: Journal of Biopharmaceutical Statistics
– volume: Accepted
  year: 2014
  article-title: A simple and flexible graphical approach for adaptive group‐sequential clinical trials
  publication-title: Journal of Biopharmaceutical Statistics
– volume: 15
  start-page: 383
  issue: 1
  year: 2014
  article-title: Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency
  publication-title: Trials
– volume: 182
  start-page: 155
  year: 2010
  end-page: 162
  article-title: Once‐daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium
  publication-title: American Journal of Respiratory and Critical Care Medicine
– volume: 82
  start-page: 69
  year: 1999
  end-page: 81
  article-title: Procedures for testing multiple endpoints in clinical trials: An overview
  publication-title: Journal of Statistical Planning and Inference
– volume: 26
  start-page: 4925
  issue: 27
  year: 2007
  end-page: 4938
  article-title: Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint
  publication-title: Statistics in Medicine
– volume: 40
  start-page: 463
  year: 2006
  end-page: 473
  article-title: Adaptive seamless phase II/III designs – background, operational aspects, and examples
  publication-title: Drug Information Journal
– volume: 20
  start-page: 2645
  year: 2001
  end-page: 2660
  article-title: Sample size recalculation using conditional power
  publication-title: Statistics in Medicine
– year: 2006
– volume: 33
  start-page: 3801
  issue: 22
  year: 2014
  end-page: 3814
  article-title: Information‐based sample size re‐estimation in group sequential design for longitudinal trials
  publication-title: Statistics in Medicine
– volume: 20
  start-page: 3741
  year: 2001
  end-page: 3751
  article-title: Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections
  publication-title: Statistics in Medicine
– volume: 14
  start-page: 36
  issue: 4
  year: 2009
  end-page: 42
  article-title: Interactions with regulatory agencies to enhance the understanding and acceptance of adaptive designs
  publication-title: Regulatory Affairs Focus
– volume: 50
  start-page: 767
  issue: 5
  year: 2008
  end-page: 781
  article-title: A comparison of methods for adaptive treatment selection
  publication-title: Biometrical Journal
– volume: 23
  start-page: 165
  year: 2010
  end-page: 171
  article-title: Integrating indacaterol dose selection in a clinical study in copd using an adaptive seamless design
  publication-title: Pulmonary Pharmacology & Therapeutics
– volume: 15
  start-page: 511
  year: 2014
  end-page: 522
  article-title: Continuous infusion of clonidine in ventilated newborns and infants: A randomized controlled trial
  publication-title: Pediatric Critical Care Medicine
– volume: 43
  start-page: 821
  issue: 7
  year: 2001
  end-page: 833
  article-title: Conditional point estimation in adaptive group sequential test designs
  publication-title: Biometrical Journal
– volume: 16
  start-page: 275
  year: 2006
  end-page: 283
  article-title: Adaptive designs in clinical drug development – an executive summary of the PhRMA working group
  publication-title: Journal of Biopharmaceutical Statistics
– volume: 55
  start-page: 853
  year: 1999
  end-page: 857
  article-title: Modification of sample size in group sequential clinical trials
  publication-title: Biometrics
– volume: 32
  start-page: 3991
  issue: 23
  year: 2013
  end-page: 4005
  article-title: Exact inference for adaptive group sequential designs
  publication-title: Statistics in Medicine
– volume: 83
  start-page: 1125
  issue: 11
  year: 2012
  end-page: 1132
  article-title: Multiple sclerosis and extract of cannabis: results of the MUSEC trial
  publication-title: Journal of Neurology Neurosurgery and Psychiatry
– year: 1999
– volume-title: Modern Adaptive Randomized Clinical Trials: Statistical, Operational, and Regulatory Aspects
  year: 2015
  ident: e_1_2_9_146_1
– ident: e_1_2_9_101_1
  doi: 10.1002/sim.3863
– ident: e_1_2_9_32_1
  doi: 10.1177/009286150103500407
– ident: e_1_2_9_73_1
  doi: 10.1002/sim.3048
– ident: e_1_2_9_115_1
  doi: 10.1111/j.1541-0420.2008.01101.x
– ident: e_1_2_9_56_1
  doi: 10.1002/sim.734
– ident: e_1_2_9_139_1
  doi: 10.1164/rccm.200910-1500OC
– ident: e_1_2_9_120_1
  doi: 10.1111/j.1541-0420.2008.01174.x
– ident: e_1_2_9_130_1
  doi: 10.1177/216847900604000408
– ident: e_1_2_9_86_1
  doi: 10.1002/sim.5377
– ident: e_1_2_9_28_1
  doi: 10.1016/0197-2456(87)90039-0
– ident: e_1_2_9_107_1
  doi: 10.1002/bimj.200390001
– ident: e_1_2_9_110_1
  doi: 10.1002/bimj.200390051
– volume-title: Adaptive Design Theory and Implementation Using SAS and R
  year: 2008
  ident: e_1_2_9_167_1
– ident: e_1_2_9_175_1
  doi: 10.1002/(SICI)1097-0258(20000415)19:7<901::AID-SIM405>3.0.CO;2-L
– ident: e_1_2_9_16_1
  doi: 10.1002/sim.1457
– volume: 40
  start-page: 421
  issue: 22
  year: 2006
  ident: e_1_2_9_131_1
  article-title: White papers
  publication-title: Drug Information Journal
– ident: e_1_2_9_47_1
  doi: 10.1198/016214502388618852
– ident: e_1_2_9_43_1
  doi: 10.2307/3109775
– ident: e_1_2_9_123_1
  doi: 10.1080/10543406.2014.925911
– ident: e_1_2_9_70_1
  doi: 10.1002/sim.3436
– ident: e_1_2_9_119_1
  doi: 10.1093/bioinformatics/btm140
– ident: e_1_2_9_4_1
  doi: 10.1080/10543400600614742
– ident: e_1_2_9_18_1
  doi: 10.1093/biomet/93.1.1
– ident: e_1_2_9_67_1
  doi: 10.1002/bimj.200510231
– volume-title: Statistical Monitoring of Clinical Trials. A Unified Approach
  year: 2006
  ident: e_1_2_9_106_1
– ident: e_1_2_9_109_1
  doi: 10.1002/sim.2258
– ident: e_1_2_9_148_1
  doi: 10.1097/PCC.0000000000000151
– year: 2015
  ident: e_1_2_9_103_1
  article-title: Adaptive seamless designs with interim treatment selection: a case study in oncology
  publication-title: Statistics in Medicine
  doi: 10.1002/sim.6407
– ident: e_1_2_9_129_1
  doi: 10.1002/pst.206
– volume-title: Draft Guidance for Industry Adaptive Design Clinical Trials for Drugs and Biologics
  year: 2010
  ident: e_1_2_9_8_1
– volume: 2443
  start-page: 3697
  year: 2005
  ident: e_1_2_9_63_1
  article-title: Testing and estimating in flexible group sequential designs with adaptive treatment selection
  publication-title: Statistics in Medicine
  doi: 10.1002/sim.2389
– ident: e_1_2_9_151_1
  doi: 10.1016/S0378-3758(99)00032-4
– ident: e_1_2_9_137_1
  doi: 10.1016/S0735-1097(01)01608-4
– ident: e_1_2_9_81_1
  doi: 10.1080/10543406.2011.554129
– ident: e_1_2_9_177_1
  doi: 10.1177/216847900604000409
– volume-title: Reflection Paper on Methodological Issues in Confirmatory Clinical Trials Planned with an Adaptive Design
  year: 2007
  ident: e_1_2_9_7_1
– ident: e_1_2_9_55_1
  doi: 10.1002/sim.1688
– volume: 3
  start-page: 279
  issue: 3
  year: 2014
  ident: e_1_2_9_124_1
  article-title: Biomarker adaptive designs in clinical trials
  publication-title: Translational Cancer Research
– ident: e_1_2_9_135_1
  doi: 10.1002/sim.2957
– ident: e_1_2_9_111_1
  doi: 10.1002/1521-4036(200111)43:7<821::AID-BIMJ821>3.0.CO;2-F
– ident: e_1_2_9_114_1
  doi: 10.1002/sim.3062
– ident: e_1_2_9_49_1
  doi: 10.1080/01621459.2012.682540
– ident: e_1_2_9_72_1
  doi: 10.1080/10543406.2014.931409
– ident: e_1_2_9_27_1
  doi: 10.1002/047005588X
– ident: e_1_2_9_68_1
  doi: 10.1080/10543406.2011.551336
– ident: e_1_2_9_75_1
  doi: 10.1002/pst.472
– ident: e_1_2_9_102_1
  doi: 10.1002/sim.4202
– ident: e_1_2_9_39_1
  doi: 10.1016/S0197-2456(00)00122-7
– volume: 20
  start-page: 130
  year: 1989
  ident: e_1_2_9_2_1
  article-title: Multistage testing with adaptive designs
  publication-title: Biometrie und Informatik in Medizin und Biologie
– ident: e_1_2_9_62_1
  doi: 10.1177/009286150003400227
– ident: e_1_2_9_54_1
  doi: 10.1002/sim.972
– ident: e_1_2_9_160_1
– ident: e_1_2_9_38_1
  doi: 10.1002/(SICI)1097-0258(19980730)17:14<1551::AID-SIM868>3.0.CO;2-E
– ident: e_1_2_9_59_1
– ident: e_1_2_9_118_1
  doi: 10.1002/sim.3716
– ident: e_1_2_9_61_1
  doi: 10.1002/sim.3538
– ident: e_1_2_9_157_1
– ident: e_1_2_9_104_1
  doi: 10.1080/10543400701645439
– ident: e_1_2_9_33_1
  doi: 10.1002/sim.6192
– ident: e_1_2_9_84_1
  doi: 10.1016/S0197-2456(97)00075-5
– ident: e_1_2_9_95_1
  doi: 10.1002/sim.2966
– ident: e_1_2_9_14_1
  doi: 10.1002/sim.6288
– ident: e_1_2_9_52_1
  doi: 10.1111/j.1541-0420.2010.01507.x
– ident: e_1_2_9_162_1
  doi: 10.32614/CRAN.package.adaptTest
– ident: e_1_2_9_24_1
  doi: 10.1111/j.0006-341X.2001.00886.x
– ident: e_1_2_9_45_1
  doi: 10.1002/(SICI)1521-4036(199906)41:3<261::AID-BIMJ261>3.0.CO;2-U
– ident: e_1_2_9_57_1
  doi: 10.1002/sim.1455
– ident: e_1_2_9_117_1
  doi: 10.1093/biomet/ast035
– ident: e_1_2_9_166_1
– ident: e_1_2_9_64_1
  doi: 10.1002/bimj.200510232
– start-page: 77
  volume-title: Practical Considerations for Adaptive Trial Design and Implementation
  year: 2014
  ident: e_1_2_9_147_1
– ident: e_1_2_9_6_1
  doi: 10.1186/1745-6215-15-383
– ident: e_1_2_9_174_1
  doi: 10.1002/sim.4780140922
– ident: e_1_2_9_41_1
  doi: 10.1002/(SICI)1521-4036(199910)41:6<689::AID-BIMJ689>3.0.CO;2-P
– ident: e_1_2_9_136_1
  doi: 10.1136/jnnp-2012-302468
– ident: e_1_2_9_12_1
  doi: 10.1002/sim.5361
– ident: e_1_2_9_99_1
  doi: 10.1080/01621459.2011.644141
– ident: e_1_2_9_171_1
  doi: 10.1002/sim.4424
– start-page: 139
  volume-title: Practical Considerations for Adaptive Trial Design And Implementation
  year: 2014
  ident: e_1_2_9_156_1
  doi: 10.1007/978-1-4939-1100-4_8
– ident: e_1_2_9_19_1
  doi: 10.1016/j.jspi.2005.08.014
– ident: e_1_2_9_153_1
  doi: 10.2307/2684438
– ident: e_1_2_9_176_1
  doi: 10.1016/S1359-6446(04)03023-5
– ident: e_1_2_9_93_1
  doi: 10.1002/sim.1136
– ident: e_1_2_9_145_1
  doi: 10.1002/sim.4179
– ident: e_1_2_9_10_1
  doi: 10.1002/sim.4780132309
– ident: e_1_2_9_122_1
– ident: e_1_2_9_76_1
  doi: 10.1002/pst.300
– ident: e_1_2_9_94_1
  doi: 10.1002/bimj.200510190
– ident: e_1_2_9_116_1
  doi: 10.1002/sim.5847
– ident: e_1_2_9_169_1
  doi: 10.1002/sim.3704
– ident: e_1_2_9_78_1
  doi: 10.1002/bimj.201300257
– ident: e_1_2_9_85_1
  doi: 10.1080/10543400701645405
– ident: e_1_2_9_149_1
  doi: 10.2307/2531158
– ident: e_1_2_9_128_1
  doi: 10.1038/nrd3079
– start-page: 77
  volume-title: Indacaterol ‐ The First Once‐Daily Long‐Acting Beta2 Agonist for COPD
  year: 2014
  ident: e_1_2_9_142_1
  doi: 10.1007/978-3-0348-0709-8_5
– ident: e_1_2_9_98_1
  doi: 10.1002/sim.6272
– ident: e_1_2_9_87_1
  doi: 10.1002/sim.3495
– year: 2014
  ident: e_1_2_9_100_1
  article-title: Adaptive survival trials
  publication-title: arXiv preprint arXiv:1405.1569
– ident: e_1_2_9_48_1
  doi: 10.1016/j.jspi.2005.08.015
– ident: e_1_2_9_60_1
  doi: 10.1093/biomet/63.3.655
– ident: e_1_2_9_163_1
– ident: e_1_2_9_26_1
  doi: 10.1201/EBK1439825488
– start-page: 77
  volume-title: Practical Considerations for Adaptive Trial Design and Implementation
  year: 2014
  ident: e_1_2_9_143_1
– ident: e_1_2_9_89_1
  doi: 10.1002/sim.3513
– ident: e_1_2_9_71_1
  doi: 10.1002/sim.6183
– ident: e_1_2_9_178_1
  doi: 10.1177/009286150904300503
– ident: e_1_2_9_90_1
  doi: 10.1002/bimj.201200218
– ident: e_1_2_9_25_1
  doi: 10.1002/sim.1852
– ident: e_1_2_9_58_1
  doi: 10.1002/sim.2180
– ident: e_1_2_9_83_1
  doi: 10.1080/10543406.2013.857238
– ident: e_1_2_9_23_1
  doi: 10.2307/2533262
– ident: e_1_2_9_15_1
  doi: 10.1093/biomet/90.2.367
– ident: e_1_2_9_168_1
  doi: 10.1002/pst.302
– ident: e_1_2_9_74_1
  doi: 10.1002/sim.3559
– ident: e_1_2_9_180_1
  doi: 10.1038/nrd4319
– ident: e_1_2_9_108_1
  doi: 10.1111/j.0006-341X.2004.00246.x
– ident: e_1_2_9_82_1
  doi: 10.1002/sim.5541
– volume: 14
  start-page: 36
  issue: 4
  year: 2009
  ident: e_1_2_9_132_1
  article-title: Interactions with regulatory agencies to enhance the understanding and acceptance of adaptive designs
  publication-title: Regulatory Affairs Focus
– ident: e_1_2_9_20_1
  doi: 10.1111/j.1541-0420.2006.00626.x
– ident: e_1_2_9_22_1
  doi: 10.1111/j.0006-341X.1999.00853.x
– ident: e_1_2_9_121_1
  doi: 10.1002/bimj.200510311
– ident: e_1_2_9_126_1
  doi: 10.1080/19466315.2013.791639
– ident: e_1_2_9_125_1
  doi: 10.1016/j.cct.2013.09.008
– ident: e_1_2_9_53_1
  doi: 10.1002/sim.531
– ident: e_1_2_9_179_1
  doi: 10.1177/2168479013486996
– volume-title: Guideline on Clinical Trials in Small Populations (chmp/ewp/83561/2005)
  year: 2006
  ident: e_1_2_9_152_1
– ident: e_1_2_9_159_1
– ident: e_1_2_9_164_1
– ident: e_1_2_9_30_1
  doi: 10.1002/sim.1362
– ident: e_1_2_9_138_1
  doi: 10.1177/2168479014522468
– ident: e_1_2_9_134_1
  doi: 10.1002/ddr.20285
– start-page: 259
  volume-title: Practical Considerations for Adaptive Trial Design and Implementation
  year: 2014
  ident: e_1_2_9_141_1
  doi: 10.1007/978-1-4939-1100-4_14
– ident: e_1_2_9_92_1
  doi: 10.1002/pst.1640
– ident: e_1_2_9_17_1
  doi: 10.1002/sim.2251
– ident: e_1_2_9_11_1
  doi: 10.1002/bimj.200510238
– ident: e_1_2_9_161_1
– ident: e_1_2_9_51_1
  doi: 10.1002/sim.2725
– ident: e_1_2_9_173_1
  doi: 10.1080/03610929208830947
– ident: e_1_2_9_37_1
  doi: 10.1198/016214502753479374
– volume-title: Statistical Methods for Meta‐Analysis
  year: 1985
  ident: e_1_2_9_35_1
– ident: e_1_2_9_65_1
  doi: 10.1080/10543400701645215
– ident: e_1_2_9_172_1
  doi: 10.1002/sim.4780110107
– ident: e_1_2_9_154_1
  doi: 10.1002/bimj.200510233
– ident: e_1_2_9_13_1
  doi: 10.1002/sim.5977
– ident: e_1_2_9_34_1
  doi: 10.1002/pst.413
– ident: e_1_2_9_3_1
  doi: 10.2307/2533441
– ident: e_1_2_9_77_1
  doi: 10.1002/bimj.200900003
– ident: e_1_2_9_170_1
  doi: 10.1002/sim.4102
– ident: e_1_2_9_5_1
  doi: 10.1002/(SICI)1097-0258(19990730)18:14<1833::AID-SIM221>3.0.CO;2-3
– volume: 31
  start-page: 663
  year: 1989
  ident: e_1_2_9_36_1
  article-title: Sequential tests of hypotheses in consecutive trials
  publication-title: Biometrical Journal
  doi: 10.1002/bimj.4710310600
– ident: e_1_2_9_46_1
  doi: 10.1002/1521-4036(200109)43:5<581::AID-BIMJ581>3.0.CO;2-J
– ident: e_1_2_9_127_1
  doi: 10.1002/bimj.200900207
– ident: e_1_2_9_113_1
  doi: 10.1002/bimj.201200245
– ident: e_1_2_9_158_1
– ident: e_1_2_9_144_1
  doi: 10.1056/NEJMoa1404710
– ident: e_1_2_9_140_1
  doi: 10.1016/j.pupt.2010.01.003
– ident: e_1_2_9_21_1
  doi: 10.1111/j.0006-341X.1999.01286.x
– ident: e_1_2_9_29_1
  doi: 10.1177/009286159302700314
– ident: e_1_2_9_155_1
  doi: 10.1198/tast.2011.10213
– ident: e_1_2_9_66_1
  doi: 10.1177/216847900604000412
– ident: e_1_2_9_69_1
  doi: 10.1002/bimj.200710453
– ident: e_1_2_9_80_1
  doi: 10.1161/CIRCULATIONAHA.108.809707
– ident: e_1_2_9_44_1
  doi: 10.1111/j.0006-341X.2004.00221.x
– ident: e_1_2_9_97_1
  doi: 10.1002/sim.1759
– ident: e_1_2_9_96_1
  doi: 10.1016/j.cct.2008.12.002
– ident: e_1_2_9_79_1
  doi: 10.1080/10543406.2014.920869
– ident: e_1_2_9_88_1
  doi: 10.1002/bimj.201000239
– volume-title: Group Sequential Methods with Applications to Clinical Trials
  year: 2000
  ident: e_1_2_9_105_1
– ident: e_1_2_9_165_1
– ident: e_1_2_9_40_1
  doi: 10.1002/(SICI)1521-4036(199906)41:3<279::AID-BIMJ279>3.0.CO;2-V
– volume: 8
  start-page: 1
  year: 2006
  ident: e_1_2_9_133_1
  article-title: Application of adaptive designs ‐ a review
  publication-title: Biometrical Journal
– ident: e_1_2_9_150_1
  doi: 10.2307/2532142
– year: 2014
  ident: e_1_2_9_91_1
  article-title: A simple and flexible graphical approach for adaptive group‐sequential clinical trials
  publication-title: Journal of Biopharmaceutical Statistics
– volume-title: Statistische Testverfahren für gruppensequentielle und adaptive Pläne in klinischen Studien. Theoretische Konzepte und deren praktische Umsetzung mit SAS
  year: 1999
  ident: e_1_2_9_42_1
– ident: e_1_2_9_112_1
  doi: 10.1002/bimj.200810442
– ident: e_1_2_9_31_1
  doi: 10.1002/bimj.201300153
– ident: e_1_2_9_50_1
  doi: 10.1002/bimj.200410042
– ident: e_1_2_9_9_1
  doi: 10.1002/sim.4780090113
– reference: 26757952 - Stat Med. 2016 Feb 10;35(3):348-9
– reference: 26757956 - Stat Med. 2016 Feb 10;35(3):364-7
– reference: 26757953 - Stat Med. 2016 Feb 10;35(3):350-8
– reference: 26757954 - Stat Med. 2016 Feb 10;35(3):359-61
– reference: 26757955 - Stat Med. 2016 Feb 10;35(3):362-3
SSID ssj0011527
Score 2.5527565
Snippet ‘Multistage testing with adaptive designs’ was the title of an article by Peter Bauer that appeared 1989 in the German journal Biometrie und Informatik in...
'Multistage testing with adaptive designs' was the title of an article by Peter Bauer that appeared 1989 in the German journal Biometrie und Informatik in...
‘Multistage testing with adaptive designs’ was the title of an article by Peter Bauer that appeared 1989 in the German journal Biometrie und Informatik in...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
istex
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 325
SubjectTerms adaptive design
Biometrics
Biometry - methods
Biostatistics
clinical trials
Clinical Trials as Topic - methods
Clinical Trials as Topic - statistics & numerical data
Data Interpretation, Statistical
Endpoint Determination - methods
Endpoint Determination - statistics & numerical data
group sequential designs
Humans
Meta-Analysis as Topic
Research Design
Sample Size
Software
Software Design
Title Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls
URI https://api.istex.fr/ark:/67375/WNG-TJ0Z7R0Z-6/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fsim.6472
https://www.ncbi.nlm.nih.gov/pubmed/25778935
https://www.proquest.com/docview/1759164194
https://www.proquest.com/docview/1760903988
https://pubmed.ncbi.nlm.nih.gov/PMC6680191
Volume 35
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BkVAlxGN5dKFURkJwyjZxHGfDDSFKqbRV1S6iKofIdmyx6jZZbXYFy4mfwG_klzCTFywUCXHKwWM5tmfG39jjzwBPI-tLJ63ytI2sJ2yiPa1C7pmhwdXZ4QrI6YLz6FDuvxMHp9Fpk1VJd2Fqfohuw40so_LXZOBKl7s_SUPLycWAuM_R_VKqFuGh4445Kmhfa6UTShkHUcs76_PdtuLaSnSNBvXzZTDzz2zJX1FstQzt3YIPbQfq7JPzwXKhB-bLb9yO_9fD23CzQafsZa1Od-CKzXtwfdScv_fgRr3Lx-rLSz3YJKxaUz3fhaPxJ_z31fev3xy6ULZCGypZ4RhG3G5CyLiYr5jK1Iw8LMuq1JHyBStmFAIs84ralak8Y7PJwqnptLwHJ3uvx6_2vebBBs8gUELPygOtEmFDi6GvVU5xxTOTCYxpNMIQ3wQu1kFsXBZrwwPp_MTEZigsxqBGhfdhIy9yuwUsE-j2QoyknE0Et1JZh7omkjC0kmOtPjxvpy41DZc5PakxTWsWZp7i2KU0dn140knOav6OS2SeVbPfCaj5OeW7xVH6_vBNOj7wz-Jj_yyVfdhu1SNtTL1MEX8hxBZBIrCtrhiNlE5eVG6LJclI2g9LhsM-PKi1qWsMfWaMoDHqQ7ymZ50AEYCvl-STjxURuJSIL5IA_79So792MD15O6Lvw38VfASbCAyr7PTA34aNxXxpHyP4WugduMrF0U5lbD8AF_wwAQ
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fb9MwED-NTYJJiD8FRmCAkRA8pUucxGngCSFGN9YKbUWbJiTLcWxRrUuqphWUJz4Cn5FPwtn5A4UhIZ7y4LMc23fn39nnnwGeRMpjminhpipSbqiS1E1FQF3Zk7g6a1wBqbngPBiy_vtw_yQ6WYMXzV2Yih-i3XAzlmH9tTFwsyG985M1tByfdw35-SXYMA9623jqsOWO8pv3Ws0ZJYv9qGGe9ehOU3NlLdoww_r5IqD5Z77krzjWLkS71-FD04Uq_-Ssu5inXfnlN3bH_-zjDbhWA1TystKom7Cm8g5cHtRH8B24Wm30ker-Ugc2DVyt2J5vwbvRJ_z55fev3zR6UbJEMypJoQkG3XpswHExWxKRialxsiSz2SPlc1JMTRSwyC27KxF5RqbjuRaTSXkbjnZfj1713frNBlciVkLnSv1UJKEKFEa_SmhBBc1kFmJYkyIS8aSv49SPpc7iVFKfaS-RseyFCsNQKYI7sJ4XuboLJAvR8wUYTGmVhFQxoTSqW5gEgWIUaznwrJk7Lms6c_OqxoRXRMyU49hxM3YOPG4lpxWFxwUyT-30twJidmZS3uKIHw_f8NG-dxofeqecObDd6Aevrb3kCMEQZYd-EmJbbTHaqTl8EbkqFkaGmS2xpNdzYKtSp7YxdJsx4sbIgXhF0VoBwwG-WpKPP1oucMYQYiQ-_r_Vo792kB_tDcz33r8KPoIr_dHggB_sDd_eh03EiTZZ3fe2YX0-W6gHiMXm6UNrcz8AvHYzRQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BK1WVKh7LK1DASAhO2ebhOAk3RFnawq6qdhFVe7Acx1ZXXZJosytYTvwEfiO_hHFesFAkxCkHj-XYnhl_Y48_AzwNlMM0U8JOVKBsquLEToTv2TKSuDprXAE9c8F5OGJ77-nBSXDSZFWauzA1P0S34WYso_LXxsCLVO_8JA0tJx_7hvv8KqxT5kRGo3ePOuoot32u1RxRstANWuJZx9tpa64sRetmVD9fhjP_TJf8FcZW69DgOpy1PajTTy76i3nSl19-I3f8vy7egGsNPCUva326CVdU1oONYXMA34OtepuP1LeXerBpwGrN9XwLDsef8N-X379-0-hDyRKNqCS5Jhhy64mBxvlsSUQqCuNiSVrljpQvSF6YGGCRVdyuRGQpKSZzLabT8jYcD16PX-3ZzYsNtkSkhK7VcxMRU-UrjH2V0MITXipTikFNgjjEka4OEzeUOg0T6blMO7EMZUQVBqFS-HdgLcszdQ9IStHv-RhKaRVTTzGhNCobjX1fMQ9rWfC8nTouGzJz86bGlNc0zB7HseNm7Cx40kkWNYHHJTLPqtnvBMTswiS8hQH_MHrDxwfOaXjknHJmwXarHryx9ZIjAEOMTd2YYltdMVqpOXoRmcoXRoaZDbE4iiy4W2tT1xg6zRBRY2BBuKJnnYBhAF8tySbnFRM4YwgwYhf_v1Kjv3aQH-8Pzff-vwo-ho3D3QF_tz96-wA2ESRWmequsw1r89lCPUQgNk8eVRb3AypYMf0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Twenty%E2%80%90five+years+of+confirmatory+adaptive+designs%3A+opportunities+and+pitfalls&rft.jtitle=Statistics+in+medicine&rft.au=Bauer%2C+Peter&rft.au=Bretz%2C+Frank&rft.au=Dragalin%2C+Vladimir&rft.au=K%C3%B6nig%2C+Franz&rft.date=2016-02-10&rft.issn=0277-6715&rft.eissn=1097-0258&rft.volume=35&rft.issue=3&rft.spage=325&rft.epage=347&rft_id=info:doi/10.1002%2Fsim.6472&rft.externalDBID=10.1002%252Fsim.6472&rft.externalDocID=SIM6472
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0277-6715&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0277-6715&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0277-6715&client=summon